

EDITORIAL INDEX

IDENTIFICATION CODES

c—Cited
cd—Clinical dialogue
efm—EFM today
et—Equal time

ed—Editorial
nl—News from the literature
oa—Original article
pr—Protocol

ppc—Problem-patient conference
s—Symposium
uc—Ultrasound clinic

NAMES

Alexander NJ: Intricacies of spermatogenesis. 225, Nov, oa
Anderson CW: Coping with complications from fetal scalp electrodes. 28, Nov, oa
Archer DF: Does prolactin affect the bone? Author's reply. 15, Jul, et
 Update from San Francisco: the 1983 AFS report. 189, Sep, c
Asch RH: Effects of marijuana on reproduction. 217, Oct, oa
Averette HE: Meeting the challenge of cervical cone biopsy. 85, Dec, oa
 Tracking an elusive entity—microinvasive cervical cancer. 151, Aug, s
Begish MS: New instruments and techniques for hysteroscopy. 67, T84, oa
Bernard G: Chemiluminescence as a biologic marker. 47, T84, oa
Barter RH: Is the mediolateral episiotomy outdated? 15, Aug, et
Baxi L: When liver disease complicates pregnancy. 59, Sep, ppc
Beall M: When liver disease complicates pregnancy. 59, Sep, ppc
Beer AE: Update from San Francisco: the 1983 AFS report. 168, Sep, c
Benedet JL: Technique for following irradiated patients. 103, Nov, oa
Benedetti TJ: Minimizing side effects from β -adrenergic tocolytics. 169, Oct, oa
Berek JS: Helping a patient surrender her child for adoption. 29, Dec, oa
 Ovarian Ca—more on cytoreduction. 68, Nov, oa
Berger GS: How to insert an IUD. 163, Sep, cd
 Paracervical block for IUD insertion. Author's reply. 17, Nov, et
Berius M: Coping successfully with cord prolapse. 196, Jul, oa
Blasco L: Consider the cervical factor in reproduction. 187, Aug, oa
Cates W Jr: Tricks of the trade in displaying data. 87, Sep, oa

What matching achieves. 171, Nov, oa
Cefalo RC: Do's and don'ts of treating pre-eclampsia and eclampsia with MgSO₄. 163, Oct, oa
 Managing missed abortion and antepartum fetal death. 17, Sep, pr
Chez RA: Fitting a diaphragm. 181, Aug, oa
 Guide to MgSO₄ therapy for PIH. 65, Dec, cd
 How to insert an IUD. 163, Sep, cd
 New diet advice for diabetics? 15, Aug, et
Cohen H: Dealing with viral hepatitis during pregnancy. 29, Sep, oa
Cohen M: Dealing with viral hepatitis during pregnancy. 29, Sep, oa
Collins WP: Chemiluminescence as a biologic marker. 47, T84, oa
Cooper MJ: Update from San Francisco: the 1983 AFS report. 174, Sep, c
Cordero L: Coping with complications from fetal scalp electrodes. 28, Nov, oa
Crum CP: Cervical condyloma and CIN: How are they related? 116, Sep, oa
 Small-cell cancer of the cervix. 119, Oct, ppc
Daniell JF Jr: Update from San Francisco: the 1983 AFS report. 169, Sep, c
DeCherney AH: Update from San Francisco: the 1983 AFS report. 170, Sep, c
DePetrillo AD: Examining patients who have had conization or hysterectomy. 99, Dec, oa
DeVore GR: How to treat nonobstetric abdominal pain in pregnancy. 47, Aug, oa
 Nonobstetric abdominal pain in pregnancy: What's the cause? 64, Jul, oa
Dicke JM: Cardiac arrhythmias in pregnant women. 158, Jul, oa
 Which therapeutic agents for cardiac arrhythmias? 187, Jul, oa
Disaia PJ: Is irradiation of gonadal tissue ever safe? Author's reply. 15, Dec, et
Dmowski WP: Update from San Francisco: the 1983 AFS report. 187, Sep, c
Duff P: Recognizing and treating toxic shock. 43, Jul, oa
Eden RD: Ultrasound and postdate pregnancy. 15, Jul, et

Ehrenkranz RA: Neonatal death: caring for the parents. 24, Sep, pr
Eisenberg E: Fertility problems of DES daughters. 197, Aug, oa
 Update from San Francisco: the 1983 AFS report. 187, Sep, c
Elias S: Gene linkage and prenatal diagnosis. 85, Oct, oa
Feingold MN: New diet advice for diabetics? Author's reply. 15, Aug, et
Ferenczy AM: Detecting endometrial cancer and precursor lesions. 231, Sep, s
 Evaluating male partners of condyloma patients. 183, Oct, oa
Freeman RK: Ensuring optimum outcome for postdate pregnancy. 186, Dec, s
 Fetal distress indicating abruptio placentae. 15, Oct, etm
 Loss of movement dictates evaluation. 15, Oct, etm
Freitak CA: New for high-risk ob—the maternal-fetal ICU. 171, Aug, oa
Fribourg S: Amniocentesis and the incompetent cervix. 16, Jul, et
Friedman MF: Is irradiation of gonadal tissue ever safe? 15, Dec, et
 Ovarian germ cell tumors. 29, Oct, et
Fu YS: Detecting endometrial cancer and precursor lesions. 231, Sep, s
Garite TJ: Fetal distress indicating abruptio placentae. 15, Oct, etm
 Loss of movement dictates evaluation. 15, Oct, etm
 What's available in EFM equipment. 17, T84, oa
Gimovsky ML: Strategy for managing breech presentation. Author's reply. 18, Jul, et
Gold WR: Managing acute adrenal insufficiency. 113, Jul, oa
Goldfarb AF: Problems linked to uterine myomas. 265, Nov, s
Goodlin RC: Contraindications to the gravity suit. 15, Sep, et
Gottesfeld KR: Managing placental abruption. 20, Dec, pr
 When the patient has placenta previa. 17, Dec, pr

Gunning JE: Contraindications to the gravity suit. Author's reply. 15, Sep, et
 For controlling intractable hemorrhage: the gravity suit. 22, Jul, oa
Gunter T: Is it time to retire "IUGR"? 15, Sep, et
Haes GG Jr: Immunologic infertility: Which approaches are best? 141, Sep, oa
Hacker NF: Ovarian Ca—more on cytoreduction. 68, Nov, oa
Hammond CB: Problems linked to uterine myomas. 265, Nov, s
Harrison MR: Progress in managing hydronephrosis in utero. 47, Oct, oa
Haseltine FP: Update from San Francisco: the 1983 AFS report. 169, Sep, c
Hayashi RH: Foreword: Preparing for the inevitable. 6, Jul, ed
Hebert DB: How to avoid or minimize urologic injuries in surgery. 213, Jul, oa
Helmkamp BF: Meeting the challenge of cervical cone biopsy. 85, Dec, oa
Hobbins JC: Spotting and treating intrauterine growth retardation. 23, Nov, pr
Holmes K: Update from San Francisco: the 1983 AFS report. 176, Sep, c
Holt RW: Guidelines for exploring the abdomen. 161, Dec, oa
Howard JT: Strategy for managing breech presentation. 18, Jul, et
Huddleston JF: Ensuring optimum outcome for postdate pregnancy. 186, Dec, s
Huggins GR: Diagnostic clues from vaginal odors. 199, Nov, oa
Jansen RPS: Update from San Francisco: the 1983 AFS report. 187, Sep, c
Johnson GH: When the pregnant patient has an abnormal Pap smear. 77, Aug, oa
Jones HW Jr: Update from San Francisco: the 1983 AFS report. 190, Sep, c
Jones WD III: What you should know about reconstructive breast surgery. 177, Nov, oa
Katz M: Minimizing side effects from β -adrenergic tocolytics. 169, Oct, oa
Kaunitz AM: Prescribing FDA-approved

EDITORIAL INDEX

IDENTIFICATION CODES

c—Cited
 cd—Clinical dialogue
 efm—EFM today
 et—Equal time

ed—Editorial
 nl—News from the literature
 oa—Original article
 pr—Protocol

ppc—Problem-patient conference
 s—Symposium
 uc—Ultrasound clinic

NAMES

Alexander NJ: Intricacies of spermatogenesis. 225, Nov, oa
Anderson CW: Coping with complications from fetal scalp electrodes. 28, Nov, oa
Archer DF: Does prolactin affect the bone? Author's reply. 15, Jul, et
 Update from San Francisco: the 1983 AFS report. 189, Sep, c
Asch RH: Effects of marijuana on reproduction. 217, Oct, oa
Averette HE: Meeting the challenge of cervical cone biopsy. 85, Dec, oa
 Tracking an elusive entity—microinvasive cervical cancer. 151, Aug, s
Begish MS: New instruments and techniques for hysteroscopy. 67, T84, oa
Bernard G: Chemiluminescence as a biologic marker. 47, T84, oa
Barter RH: Is the mediolateral episiotomy outdated? 15, Aug, et
Baxi L: When liver disease complicates pregnancy. 59, Sep, ppc
Beall M: When liver disease complicates pregnancy. 59, Sep, ppc
Beer AE: Update from San Francisco: the 1983 AFS report. 168, Sep, c
Benedetti JL: Technique for following irradiated patients. 103, Nov, oa
Benedetti TJ: Minimizing side effects from β -adrenergic tocolytics. 169, Oct, oa
Berek JS: Helping a patient surrender her child for adoption. 29, Dec, oa
 Ovarian Ca—more on cytoreduction. 68, Nov, oa
Berger GS: How to insert an IUD. 163, Sep, cd
 Paracervical block for IUD insertion. Author's reply. 17, Nov, et
Berius M: Coping successfully with cord prolapse. 196, Jul, oa
Blasco L: Consider the cervical factor in reproduction. 187, Aug, oa
Cates W Jr: Tricks of the trade in displaying data. 87, Sep, oa

What matching achieves. 171, Nov, oa
Cefalo RC: Dos and don'ts of treating pre-eclampsia and eclampsia with MgSO₄. 163, Oct, oa
 Managing missed abortion and antepartum fetal death. 17, Sep, pr
Chez RA: Fitting a diaphragm. 181, Aug, oa
 Guide to MgSO₄ therapy for PIH. 65, Dec, cd
 How to insert an IUD. 163, Sep, cd
 New diet advice for diabetics? 15, Aug, et
Cohen H: Dealing with viral hepatitis during pregnancy. 29, Sep, oa
Cohen M: Dealing with viral hepatitis during pregnancy. 29, Sep, oa
Collins WP: Chemiluminescence as a biologic marker. 47, T84, oa
Cooper MJ: Update from San Francisco: the 1983 AFS report. 174, Sep, c
Cordero L: Coping with complications from fetal scalp electrodes. 28, Nov, oa
Crum CP: Cervical condyloma and CIN: How are they related? 116, Sep, oa
 Small-cell cancer of the cervix. 119, Oct, ppc
Daniell JF Jr: Update from San Francisco: the 1983 AFS report. 169, Sep, c
DeCherney AH: Update from San Francisco: the 1983 AFS report. 170, Sep, c
DePetrillo AD: Examining patients who have had coitus or hysterectomy. 99, Dec, oa
DeVore GR: How to treat nonobstetric abdominal pain in pregnancy. 47, Aug, oa
 Nonobstetric abdominal pain in pregnancy: What's the cause? 64, Jul, oa
Dicke JM: Cardiac arrhythmias in pregnant women. 158, Jul, oa
 Which therapeutic agents for cardiac arrhythmias? 187, Jul, oa
Disaia PJ: Is irradiation of gonadal tissue ever safe? Author's reply. 15, Dec, et
Dmowski WP: Update from San Francisco: the 1983 AFS report. 187, Sep, c
Duff P: Recognizing and treating toxic shock. 43, Jul, oa
Eden RD: Ultrasound and postdate pregnancy. 15, Jul, et

Ehrenkranz RA: Neonatal death: caring for the parents. 24, Sep, pr
Eisenberg E: Fertility problems of DES daughters. 197, Aug, oa
 Update from San Francisco: the 1983 AFS report. 187, Sep, c
Elias S: Gene linkage and prenatal diagnosis. 85, Oct, oa
Feingold MN: New diet advice for diabetics? Author's reply. 15, Aug, et
Ferenczy AM: Detecting endometrial cancer and precursor lesions. 231, Sep, s
 Evaluating male partners of condyloma patients. 183, Oct, oa
Freeman RK: Ensuring optimum outcome for postdate pregnancy. 186, Dec, s
 Fetal distress indicating abruptio placentae. 15, Oct, et
Ganley S: Amniocentesis and the incompetent cervix. 16, Jul, et
Garrison MF: Is irradiation of gonadal tissue ever safe? 15, Dec, et
 Ovarian germ cell tumors. 29, Oct, et
Fu YS: Detecting endometrial cancer and precursor lesions. 231, Sep, s
Garite TJ: Fetal distress indicating abruptio placentae. 15, Oct, et
 Loss of movement dictates evaluation. 15, Oct, et
Freitas CA: New for high-risk ob—the maternal-fetal ICU. 171, Aug, oa
Fribourg S: Amniocentesis and the incompetent cervix. 16, Jul, et
Friedman MF: Is irradiation of gonadal tissue ever safe? 15, Dec, et
Goldfarb AF: Problems linked to uterine myomas. 265, Nov, s
Goodlin RC: Contraindications to the gravity suit. 15, Sep, et
Gottesfeld KR: Managing placental abruption. 20, Dec, pr
 When the patient has placenta previa. 17, Dec, pr
Gunning JE: Contraindications to the gravity suit. Author's reply. 15, Sep, et
 For controlling intractable hemorrhage: the gravity suit. 22, Jul, oa
Gunter T: Is it time to retire "IUGR"? 15, Sep, et
Haes GG Jr: Immunologic infertility: Which approaches are best? 141, Sep, oa
Hacker NF: Ovarian Ca—more on cytoreduction. 68, Nov, oa
Hammond CB: Problems linked to uterine myomas. 265, Nov, s
Harrison MR: Progress in managing hydronephrosis in utero. 47, Oct, oa
Haseltine FP: Update from San Francisco: the 1983 AFS report. 169, Sep, c
Hayashi RH: Foreword: Preparing for the inevitable. 6, Jul, ed
Hebert DB: How to avoid or minimize urologic injuries in surgery. 213, Jul, oa
Helmkamp BF: Meeting the challenge of cervical cone biopsy. 85, Dec, oa
Hobbins JC: Spotting and treating intrauterine growth retardation. 23, Nov, pr
Holmes K: Update from San Francisco: the 1983 AFS report. 176, Sep, c
Holt RW: Guidelines for exploring the abdomen. 161, Dec, oa
Howard JT: Strategy for managing breech presentation. 18, Jul, et
Huddleston JF: Ensuring optimum outcome for postdate pregnancy. 186, Dec, s
Huggins GR: Diagnostic clues from vaginal odors. 199, Nov, oa
Jansen RPS: Update from San Francisco: the 1983 AFS report. 187, Sep, c
Johnson GH: When the pregnant patient has an abnormal Pap smear. 77, Aug, oa
Jones HW Jr: Update from San Francisco: the 1983 AFS report. 190, Sep, c
Jones WD III: What you should know about reconstructive breast surgery. 177, Nov, oa
Katz M: Minimizing side effects from β -adrenergic tocolytics. 169, Oct, oa
Kaunitz AM: Prescribing FDA-approved

drugs in nonapproved ways. 27, Aug, oa

Keith L: Fitting a diaphragm. 181, Aug, oa

Kelly RW: Update from San Francisco: the 1983 AFS report. 169, Sep, c

Kempers RD: Problems linked to uterine myomas. 265, Nov, s

Klein MP: Strategy for managing breech presentation. 16, Jul, et

Knobell E: Update from San Francisco: the 1983 AFS report. 167, Sep, c

Kohn T: Evaluating the male partners of condyloma patients. 183, Oct, oa

Koontz WL: Dos and don'ts of treating pre-eclampsia and eclampsia with MgSO₄. 163, Oct, oa

Koplan JP: CDC urges vaccinating adults as rubella in children disappears. 246, Dec, n

Krebs HB: Meeting the challenge of cervical cone biopsy. 85, Dec, oa

Kurman RJ: Detecting endometrial cancer and precursor lesions. 231, Sep, s

Lagasse LD: Ovarian Ca—more on cytoreduction. 68, Nov, oa

Lefkowitz J: When liver disease complicates pregnancy. 59, Sep, ppc

Levine RU: Cervical condyloma and CIN: How are they related? 116, Sep, oa

Lipsett MB: Update from San Francisco: the 1983 AFS report. 167, Sep, c

Lipshitz J: Expanding the role of β -symathomimetic drugs in obstetric emergencies. 122, Jul, oa

Lorenz RP: Computer applications in the ob-gyn office. 71, Dec, oa

Lundy J: Lumps: When is close follow-up appropriate? 196, Sep, oa

What treatment alternatives for minimal breast cancer? 107, Oct, oa

Machol L: Update from San Francisco: the 1983 AFS report. 167, Sep, oa

Mahan CS: How worthwhile are membrane stripping and amniotomy? 173, Dec, oa

Preps and enemas—keep or discard? 241, Nov, oa

Mann WJ: Ovarian germ cell tumors. Author's reply. 29, Oct, et

March CM: Update from San Francisco: the 1983 AFS report. 170, Sep, c

Marks F: When liver disease complicates pregnancy. 59, Sep, ppc

Marlow JL: Current role of CO₂ lasers in ob-gyn surgery. 107, T84, oa

Mateo-Woodburn CV: Choosing anesthesia for high-risk ob patients. 75, Sep, oa

McKay S: How worthwhile are membrane stripping and amniotomy? 173, Dec, oa

Preps and enemas—keep or discard? 241, Nov, oa

Mestman JH: Thyroid storm need not be lethal. 135, Aug, oa

Modanlou HD: Guide to sinusoidal FHR patterns. 94, Aug, oa

Murphy KJ: Technique for following irradiated patients. 103, Nov, oa

Nelson JH: Tracking an elusive entity—microinvasive cervical cancer. 151, Aug, oa

Ober WB: Little-known ob-gyn milestone—Mendelson on gastric aspiration. 95, Oct, oa

Oki EY: Protocol for the nipple-stimulation CST. 157, Oct, oa

Olsen TG: Your pregnant patient's rash: Is it PUPP syndrome? 151, Dec, oa

O'Malley BW: How recombinant DNA technology may transform medicine and industry. 203, Aug, oa

Orr JW Jr: Choosing the best urinary diversion for gyn patients. 253, Nov, oa

Ory HW: What matching achieves. 171, Nov, oa

Part RC: Tracking an elusive entity—microinvasive cervical cancer. 151, Aug, oa

Patterson RM: Pediatric gyn trauma. 147, Jul, oa

Petrie RH: Ensuring optimum outcome for postdate pregnancy. 186, Dec, s

Pfeffer WH: How to choose sutures for microsurgery. 87, Nov, oa

Pillerasdorf A: Guidelines for exploring the abdomen. 161, Dec, oa

Pretil G: Diagnostic clues from vaginal odors. 199, Nov, oa

Pringle P: How to select a cryosurgical unit. 101, T84, oa

Update on colposcopes and their accessories. 85, T84, oa

Queenan JT: Breast disease—first line of defense. 11, Sep, ed

Closing the book on Rh disease. 9, Oct, ed

Ethical decisions: individual or consensus? 11, Jul, ed

Malpractice update. 11, Dec, ed

Managing polyhydramnios. 17, Aug, pr

Managing Rh immunization. 33, Oct, pr

Old questions about a new procedure. 3, T84, ed

Prepping vs. plumbing. 21, Jul, et

What can we do for Mrs. Smith? 11, Nov, ed

What to do when a surgical wound separates. 35, Jul, oa

Work and pregnancy: guidelines needed. 9, Aug, ed

Quigley MM: Update from San Francisco: the 1983 AFS report. 190, Sep, c

Rapp F: Herpesviruses: why control is difficult. 61, Aug, oa

Ravnikar VA: Does prolactin affect the bone? 15, Jul, et

Reed ML: What you should know about reconstructive breast surgery. 177, Nov, oa

Reese WD: Better way to screen for osteoporosis. 116, Nov, oa

Richardson BS: Fetal activity: measure of well-being. 211, Sep, oa

Richtart RM: Detecting endometrial cancer and precursor lesions. 231, Sep, s

How to select a cryosurgical unit. 101, T84, oa

Small-cell cancer of the cervix. 119, Oct, ppc

Tracking an elusive entity—microinvasive cervical cancer. 151, Aug, oa

Update on colposcopes and their accessories. 85, T84, oa

Ridderick DH: How to induce ovulation. 199, Oct, s

Update from San Francisco: the 1983 AFS report. 169, Sep, c

Rodeck CH: Chorionic villi sampling: its promise and its problems. Potential for improving fetal treatment. 38, T84, oa

Rogers BJ: Update from San Francisco: the 1983 AFS report. 180, Sep, c

Rosenblatt A: Pill's many noncontraceptive benefits. 136, Oct, oa

Roy M: Colposcopic patterns of papillomavirus infection. 107, Sep, oa

Rubio T: Small-cell cancer of the cervix. 119, Oct, ppc

Sanders RC: Problems in diagnosing hydronephrosis in utero. 80, Oct, oa

Scanning the pelvis for neoplasia. 115, Dec, oa

Santos AC: Obstetric use of local anesthetics. 46, Dec, oa

Schenk RS: Update from San Francisco: the 1983 AFS report. 184, Sep, c

Schoenbacher AK: Paracervical block for IUD insertion. 17, Nov, et

Schreiber JR: New insights into follicular development. 125, Dec, oa

Schultz TZ: How recombinant DNA technology may transform medicine and industry. 203, Aug, oa

Schwarz RH: Management of amnionitis. 19, Nov, pr

Scianni AR: Safe medications during pregnancy. 40, Nov, oa

Seibel M: Update from San Francisco: the 1983 AFS report. 188, Sep, c

Shen J: Small-cell cancer of the cervix. 119, Oct, ppc

Shepard M: How to manage the victim of rape. 253, Sep, oa

Shore M: Evaluating male partners of condyloma patients. 183, Oct, oa

Siddle N: Flexible prescribing of estrogens. 137, Nov, oa

Slinger PA: Thyroid storm need not be lethal. 135, Aug, oa

Smith CG: Effects of marijuana on reproduction. 217, Oct, oa

Smith WG: When the pregnant patient has an abnormal Pap smear. 77, Aug, oa

Speroff L: How to induce ovulation. 199, Oct, s

PMS—looking for new answers to an old problem. 102, Aug, oa

Symonds EM: NMR—new tool for ob-gyn imaging. 9, T84, oa

Tarter TH: Intricacies of spermatogenesis. 225, Nov, oa

Taylor SN: Update from San Francisco: the 1983 AFS report. 169, Sep, c

Thorneycroft IH: When you suspect ectopic pregnancy. 91, Jul, oa

Turnbull JM: When to refer psychiatric problems. 249, Nov, oa

Wallach EE: Problems linked to uterine myomas. 265, Nov, s

Update from San Francisco: the 1983 AFS report. 189, Sep, c

Ward H: Chorionic villi sampling: its promise and its problems. A source of fetal cells. 31, T84, oa

Warsol SL: Using the computer to estimate fetal weight. 25, T84, oa

Weinberg PC: When to refer psychiatric problems. 249, Nov, oa

Weinstein FG: Update from San Francisco: the 1983 AFS report. 189, Sep, c

White CC: CDC urges vaccinating adults as rubella in children disappears. 246, Dec, n

Whitehead M: Flexible prescribing of estrogens. 137, Nov, oa

Willcourt RJ: New for high-risk ob—the maternal-fetal ICU. 171, Aug, oa

Williams G: When liver disease complicates pregnancy. 59, Sep, ppc

Work, BA Jr: Is the mediolateral episiotomy outdated? Author's reply. 15, Aug, et

Worley R: How to induce ovulation. 199, Oct, s

Worthington BS: NMR—new tool for ob-gyn imaging. 9, T84, oa

Yeast JD: What's available in EFM equipment. 17, T84, oa

Yonezawa R: Minimizing side effects from β -adrenergic tocolytics. 169, Oct, oa

Zuspan FP: Guide to MgSO₄ therapy for PIH. 65, Dec, cd

When your patient has pregnancy-induced hypertension. 36, Oct, pr

SUBJECTS

ABNORMALITIES (see also CHROMOSOME ABNORMALITIES)

Dealing with hepatitis during pregnancy. 34, Sep, oa

Ethical decisions: individual or consensus? 11, Jul, ed

How NICU babies fare after discharge. 240, Oct, n

Is irradiation of gonadal tissue ever safe? 15, Dec, et

Is irradiation of gonadal tissue ever safe? Author's reply. 15, Dec, et

Managing missed abortion and antepartum fetal death. 17, Sep, pr

Managing polyhydramnios. 25, Aug, pr

Neonatal death: caring for the parents. 24, Sep, pr

Problems in diagnosing hydronephrosis in utero. 80, Oct, oa

Problems linked to uterine myomas. 273, Nov, s

Progress in managing hydronephrosis in utero. 47, Oct, oa

For cures you can count on

Monistat 7[®] Vaginal Cream

(miconazole nitrate 2%)

Highly effective...
low rate of relapse

MONISTAT 7 Vaginal Cream (miconazole nitrate 2%)
Description: MONISTAT 7 Vaginal Cream (miconazole nitrate 2%) is a water-miscible, white cream containing as the active ingredient, 2% miconazole nitrate, 1-[2,4-dichloro- β -(2,4-dichlorobenzoyloxy)phenethyl] imidazole nitrate.

Actions: MONISTAT 7 Vaginal Cream exhibits fungicidal activity *in vitro* against species of the genus *Candida*. The pharmacologic mode of action is unknown.

Indications: MONISTAT 7 Vaginal Cream is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As MONISTAT 7 Vaginal Cream is effective only for candidal vulvovaginitis, the diagnosis should be confirmed by KOH smears and/or cultures. Other pathogens commonly associated with vulvovaginitis (*Trichomonas* and *Haemophilus vaginalis* [*Gardnerella*]) should be ruled out by appropriate laboratory methods.

MONISTAT 7 is effective in both pregnant and non-pregnant women, as well as in women taking oral contraceptives. (See Precautions.)

Contraindications: Patients known to be hypersensitive to this drug.

Precautions: General: Discontinue drug if sensitization or irritation is reported during use. Laboratory Tests: If there is a lack of response to MONISTAT 7, appropriate microbiological studies should be repeated to confirm the diagnosis and rule out other pathogens.

Pregnancy: Since MONISTAT is absorbed in small amounts from the human vagina, it should be used in the first trimester of pregnancy only when the physician considers it essential to the welfare of the patient.

Clinical studies, during which MONISTAT was used for 14 days, included 209 pregnant patients. Follow-up reports now available in 117 of these patients reveal no adverse effects or complications attributable to MONISTAT therapy in infants born to these women.

Adverse Reactions: During clinical studies with MONISTAT for a 14-day regimen, 39 of the 528 patients (7.4%) treated with MONISTAT reported complaints during therapy that were possibly drug-related. Most complaints were reported during the first week of therapy. Vulvovaginal burning, itching or irritation occurred in 6.6%, while other complaints such as vaginal burning, pelvic cramps, hives, skin rash and headache occurred rarely (each less than 0.2% patient incidence). The therapy-related dropout rate was 0.9%.

Clinical: Statistical analysis of randomized clinical trials, conducted to determine the shortest effective course of therapy with MONISTAT, demonstrates that a regimen of seven or more days has a cure rate equivalent to the 14-day regimen.


The graphic representation of this conclusion plots days of therapy versus cure rates. The solid line represents the mean therapeutic cure rate and the shaded area represents the 95% confidence interval.

Dosage and Administration: One applicatorful is administered intravaginally once daily at bedtime for seven days. Course of therapy may be repeated after other pathogens have been ruled out by appropriate smears and cultures.

Supplied: MONISTAT 7 Vaginal Cream is available in 1.66 oz. (47 g) tubes with ORTHO[®] Measured-Dose Applicator.

[®]Trademark

ORTHO PHARMACEUTICAL CORPORATION
Raritan, New Jersey 08869



EDITORIAL INDEX

Strategy for managing breech presentation.
Author's reply. 20, Jul, et

ABNORMALITIES, DRUG-INDUCED
Minimizing side effects from β -adrenergic tocolytics. 179, 197, Oct, oa

Safe medications during pregnancy. 40, Nov, oa

ABORTION
Fertility problems of DES daughters. 198, 199, Aug, oa

Risk factors for cervical injury in suction D & E. 280, Nov, nl

ABORTION, HABITUAL
Update from San Francisco: the 1983 AFS report. 168, 169, Sep, oa

ABORTION, MISSED
Managing missed abortion and antepartum fetal death. 17, Sep, pr

ABRUPTIO PLACENTAE
Fetal distress indicating abruptio placentae. 16, Oct, et

When your patient has pregnancy-induced hypertension. 36, Oct, pr

ABSCESS
Coping with complications from fetal scalp electrodes. 28, 29, 30, Nov, oa

ACETAMINOPHEN
Thyroid storm need not be lethal. 137, Aug, oa

ACIDOSIS
For controlling intractable hemorrhage: the gravity suit. 32, Jul, oa

Obstetric use of local anesthetics. 57, 58, Dec, oa

ACIDS, ALIPHATIC
Diagnostic clues from vaginal odors. 205, 206, 212, Nov, oa

ACYLOVIR
Herpesviruses: why control is difficult. 74, Aug, oa

ADDISON'S DISEASE
Managing acute adrenal insufficiency. 113, Jul, oa

ADENOCARCINOMA
Detecting endometrial cancer and precursor lesions. 239, 243, Sep, s

ADENOMA
Pill's many noncontraceptive benefits. 136, Oct, oa

ADENOSINE TRIPHOSPHATASE
Chemiluminescence as a biologic marker. 48, 57, 60, 63, T84, oa

ADHESIONS
Update from San Francisco: the 1983 AFS report. 169, 170, Sep, oa

ADNEAL DISEASES
Prescribing FDA-approved drugs in nonapproved ways. 36, Aug, oa

ADNEXITIS
Incidence of ectopics rising in US. 240, Oct, nl

Pill's many noncontraceptive benefits. 137, 140, 143, 150, Oct, oa

Update from San Francisco: the 1983 AFS report. 176, 180, 184, Sep, oa

ADOLESCENCE
Cervical cancer risk for teenage smokers. 238, Oct, nl

Teaching adolescents to examine breasts. 266, Sep, nl

ADOPTION
Helping a patient surrender her child for adoption. 29, Dec, oa

ADRENAL CORTEX DISEASES
Managing acute adrenal insufficiency. 113, Jul, oa

ADRENAL CORTEX HORMONES
Immunologic infertility: Which approaches are best? 155, 156, Sep, oa

Managing acute adrenal insufficiency. 114, Jul, oa

Thyroid storm need not be lethal. 144, Aug, oa

AGE FACTORS
Cervical condyloma and CIN: How are they related? 117, 122, Sep, oa

Exogenous estrogens reverse some age-related changes. 238, Oct, nl

Incidence of ectopics rising in US. 240, Oct, nl

Over-40 OC users' risk for cancer down. 239, Oct, nl

Problems linked to uterine myomas. 278, 279, Nov, s

Risk factors for cervical injury in suction D & E. 280, Nov, nl

Tracking an elusive entity—microinvasive cervical cancer. 169, Aug, s

What can we do for Mrs. Smith? 11, Nov, ed

AIDS
Women at risk for AIDS. 266, Sep, nl

ALCOHOL DRINKING
Fetal activity: measure of well-being. 219, 220, Sep, oa

ALDOSTERONE
PMS—looking for new answers to an old problem. 109, Aug, oa

ALLERGY AND IMMUNOLOGY
PMS—looking for new answers to an old problem. 102, Aug, oa

ALPHA FETOPROTEINS
ACOG on AFP screening. 264, Sep, nl

New assay for confirming fetal NTDs. 247, Dec, nl

Ovarian germ cell tumors. 29, Oct, et

AMERICAN FERTILITY SOCIETY
Update from San Francisco: the 1983 AFS report. 167, Sep, oa

AMINO ACIDS
Diagnostic clues from vaginal odors. 199, 200, Nov, oa

AMINOPHYLLINE
Little-known ob-gyn milestone—Mendelson on gastric aspiration. 101, Oct, oa

AMNIOCENTESIS
Amniocentesis and the incompetent cervix. 16, Jul, et

Ensuring optimum outcome for postdate pregnancy. 201, 204, Dec, s

Management of amniocentesis. 19, Nov, pr

Managing polyhydramnios. 21, Aug, pr

Managing Rh immunization. 34, 36, Oct, pr

Old questions about a new procedure. 3, 6, T84, ed

AMNIONITIS
Management of amniocentesis. 19, Nov, pr

AMNIOSCOPY Ensuring optimum outcome for postdate pregnancy. 200, 204, Dec, s

AMNIOTIC BAND SYNDROME Expanding the role of β -sympathomimetic drugs in obstetric emergencies. 140, Jul, oa

AMNIOTIC FLUID Amniocentesis and the incompetent cervix. 16, Jul, et

Managing polyhydramnios. 17, Aug, pr

New assay for confirming fetal NTDs. 247, Dec, nl

Problems in diagnosing hydronephrosis in utero. 81, 82, Oct, oa

Progress in managing hydronephrosis in utero. 52, 54, 60, Oct, oa

Spotting and treating intrauterine growth retardation. 23, Nov, pr

Ultrasound and postdate pregnancy. 15, Jul, et

AMNIOTOMY How worthwhile are membrane stripping and amniotomy? 175, 176, 179, 181, Dec, oa

AMYLASES Nonobstetrical abdominal pain in pregnancy: What's the cause? 77, 78, Jul, oa

ANATOMY, DEVELOPMENTAL How to induce ovulation. 202, Oct, s

Pediatric gyn trauma. 147, Jul, oa

Pill's many noncontraceptive benefits. 136, 137, Oct, oa

ANDROGENS How to induce ovulation. 202, Oct, s

ANEMIA Pill's many noncontraceptive benefits. 136, Oct, oa

ANESTHESIA Current role of CO₂ lasers in ob-gyn surgery. 117, T84, oa

Risk factors for cervical injury in suction D & E. 280, Nov, nl

Tracking tubal sterilization deaths. 223, Aug, nl

ANESTHESIA, CONDUCTION Choosing anesthesia for high-risk ob patients. 80, 82, 83, 84, Sep, oa

ANESTHESIA, EPIDURAL Choosing anesthesia for high-risk ob patients. 80, Sep, oa

ANESTHESIA, GENERAL Choosing anesthesia for high-risk ob patients. 75, 76, Sep, oa

ANESTHESIA, INHALATION Little-known ob-gyn milestone—Mendelson on gastric aspiration. 95, Oct, oa

ANESTHESIA, LOCAL How to insert an IUD. 163, 164, Sep, cd

Obstetric use of local anesthetics. 46, Dec, oa

Paracervical block for IUD insertion. 17, Nov, et

Paracervical block for IUD insertion. Author's reply. 17, Nov, et

ANESTHESIA, OBSTETRICAL Choosing anesthesia for high-risk ob patients. 75, Sep, oa

ANESTHESIA, REGIONAL (see ANESTHESIA, CONDUCTION)

ANESTHESIA, SPINAL Choosing anesthesia for high-risk ob patients. 76, 80, Sep, oa

ANEUPLOIDY Cervical condyloma and CIN: How are they related? 118, 122, Sep, oa

ANOVULATION How to induce ovulation. 199, Oct, s

Prescribing FDA-approved drugs in nonapproved ways. 32, Aug, oa

ANTACIDS How to treat nonobstetric abdominal pain in pregnancy. 50, Aug, oa

ANTIARRHYTHMIA AGENTS Which therapeutic agents for cardiac arrhythmias? 187, Jul, oa

ANTIBIOTICS How to treat nonobstetric abdominal pain in pregnancy. 47, 48, Aug, oa

Little-known ob-gyn milestone—Mendelson on gastric aspiration. 101, Oct, oa

Management of amniotitis. 19, 22, Nov, pr

Pediatric gyn trauma. 149, 155, Jul, oa

Recognizing and treating toxic shock. 55, Jul, oa

ANTIBODIES Immunologic infertility: Which approaches are best? 141, Sep, oa

ANTICOAGULANTS Cardiac arrhythmias in pregnant women. 166, Jul, oa

ANTIDEPRESSANTS When to refer psychiatric emergencies. 250, Nov, oa

ANTIGEN-ANTIBODY REACTIONS Immunologic infertility: Which approaches are best? 141, Sep, oa

ANTIGENS Immunologic infertility: Which approaches are best? 141, Sep, oa

APPENDICOTOMY Ovarian Ca—mole on cytoreduction. 69, Nov, oa

APPENDICITIS How to treat nonobstetric abdominal pain in pregnancy. 47, Aug, oa

Nonobstetric abdominal pain in pregnancy: What's the cause? 65, 66, 68, 71, Jul, oa

APUDOMA Small-cell cancer of the cervix. 120, 121, 131, Oct, ppc

ARGYROPHILIC CELLS Small-cell cancer of the cervix. 121, Oct, ppc

AROUSAL Diagnostic clues from vaginal odors. 213, 216, Nov, oa

ARRHYTHMIAS Cardiac arrhythmias in pregnant women. 158, Jul, oa

Which therapeutic agents for cardiac arrhythmias? 187, Jul, oa

ARRHYTHMIAS, SINUS Cardiac arrhythmias in pregnant women. 170, 171, Jul, oa

ARTHRITIS, RHEUMATOID Pill's many noncontraceptive benefits. 143, Oct, oa

ARTIFICIAL INSEMINATION Immunologic infertility: Which approaches are best? 155, 156, Sep, oa

ASCITES Progress in managing hydronephrosis. 57, 58, 66, Oct, oa

ATRIAL FIBRILLATION Cardiac arrhythmias in pregnant women. 164, 166, Jul, oa

ATRIAL FLUTTER Cardiac arrhythmias in pregnant women. 163, 164, Jul, oa

ATROPHINE Little-known ob-gyn milestone—Mendelson on gastric aspiration. 101, Oct, oa

ATTITUDE TO DEATH Managing missed abortion and antepartum fetal death. 23, Sep, pr

Neonatal death: caring for the parents. 24, Sep, pr

AUTOPSY Neonatal death: caring for the parents. 24, Sep, pr

BACTERIA How recombinant DNA technology may transform medicine and industry. 203, Aug, oa

BACTERIAL METABOLISM Diagnostic clues from vaginal odors. 206, 212, Nov, oa

BASAL BODY TEMPERATURE How to induce ovulation. 202, 204, 205, Oct, s

BEHAVIORAL STATES, NEONATAL Fetal activity: measure of well-being. 211, Sep, oa

BENADRYL Prescribing FDA-approved drugs in nonapproved ways. 27, Aug, oa

BETA-ADRENERGICS Minimizing side effects from β -adrenergic antagonists. 169, Oct, oa

BILE Nonobstetrical abdominal pain in pregnancy: What's the cause? 71, 72, Jul, oa

BIOLUMINESCENCE (see CHEMILUMINESCENCE)

BIOPSY Detecting endometrial cancer and precursors. 247, Sep, s

Examining patients who have had conization or hysterectomy. 99, Dec, oa

How to induce ovulation. 204, 205, 206, Oct, s

Lumps: When is close follow-up appropriate? 204, 205, 209, Sep, oa

Meeting the challenge of cervical cone biopsy. 85, Dec, oa

Technique for following irradiated patients. 103, Nov, oa

Tracking an elusive entity—microinvasive cervical cancer. 151, 152, Aug, s

What treatment alternatives for minimal breast cancer? 107, Oct, oa

When liver disease complicates pregnancy. 60, 64, 65, 68, 73, Sep, ppc

When the pregnant patient has an abnormal Pap smear. 77, 79, 86, Aug, oa

Biopsy, NEEDLE Aspiration smears for breast lesion diagnosis. 266, Sep, nl

BIPARIETAL DIAMETER Using the computer to estimate fetal weight. 25, T84, oa

BLOOD CELL COUNT Managing missed abortion and antepartum fetal death. 22, Sep, pr

When you suspect ectopic pregnancy. 91, Jul, oa

BLOOD FLOW VELOCITY Doppler ultrasound detects patent ductus arteriosus early. 221, Aug, nl

BLOOD GLUCOSE New diet advice for diabetics? Author's reply. 15, Aug, et

BLOOD TRANSFUSION, AUTOLYSIS For controlling intractable hemorrhage: the gravity test. 23, 24, Jul, oa

BLOOD TRANSFUSION, INTRAUTERINE Closing the book on Rh disease. 9, Oct, ed

Guide to sinusoidal FHR patterns. 94, Aug, oa

BODY TEMPERATURE Intricacies of spermatogenesis. 236, Nov, oa

BONE AND BONES Better way to screen for osteoporosis. 116, Nov, oa

Does prolactin affect the bone? 15, Jul, et

Does prolactin affect the bone? Author's reply. 15, Jul, et

Nonhormonal approach to osteoporosis delayed. 280, Nov, nl

BONE DISEASES Better way to screen for osteoporosis. 116, Nov, oa

BRADYCARDIA Cardiac arrhythmias in pregnant women. 170, 171, Jul, oa

BREAST DISEASES Breast disease—first line of defense. 11, Sep, ed

Lumps: When is close follow-up appropriate? 196, Sep, oa

Palpation adequate for annual breast exam. 264, Sep, nl

Pill's many noncontraceptive benefits. 143, Oct, oa

Teaching adolescents to examine breasts. 266, Sep, nl

What you should know about reconstructive breast surgery. 177, Nov, oa

BREAST-FEEDING Dealing with viral hepatitis during pregnancy. 48, Sep, oa

Diet for preterm infants. 237, Oct, nl

BREAST NEOPLASMS Aspiration smears for breast lesion diagnosis. 266, Sep, nl

Breast disease—first line of defense. 11, Sep, ed

How tumor growth rate affects outcome. 264, Sep, nl

The confidence of sound nutrition in yet another generation

STUARTNATAL® 1+1 TABLETS

Vitamins:	One tablet provides	% U.S. RDA*
A	8,000 I.U.	100%
D	400 I.U.	100%
E	30 I.U.	100%
C	90 mg.	150%
Folic Acid	1 mg.	125%
Thiamine	2.55 mg.	150%
Riboflavin	3 mg.	150%
Niacin	20 mg.	100%
B ₆	10 mg.	400%
B ₁₂	12 mcg.	150%

Minerals:

Calcium	200 mg.	15%
Iodine	150 mcg.	100%
Iron	65 mg.	361%
Magnesium	100 mg.	22%

* U.S. Recommended Daily Allowance for pregnant or lactating women.

Indication: To provide potent vitamin and mineral supplementation throughout pregnancy and during the postnatal period—for both the lactating and non-lactating mother.

Precaution: Folic acid may partially correct the hematological damage due to Vitamin B₁₂ deficiency of pernicious anemia, while the associated neurological damage progresses.

Dosage and Administration: During and after pregnancy, one tablet daily after a meal, or as directed by a physician.

References: 1. Maternal nutrition and the course of pregnancy. Committee on Maternal Nutrition, Food and Nutrition Board, National Research Council, National Academy of Sciences, Washington, DC, 1970, pp 74-109. 2. Data on file, Stuart Pharmaceuticals. 3. Seligman PA, Caskey JH, Frazier JL, Allen RH, et al: Measurements of iron absorption from prenatal multivitamin-mineral supplements. *Obstet Gynecol* 1983;61:356-362.



STUART PHARMACEUTICALS
Division of ICI Americas Inc.
Wilmington, Delaware 19897

EDITORIAL INDEX

Lumps: When is close follow-up appropriate? 196, Sep, oa
 Lymph node x-rays as possible prognostic indicators. 237, Oct, nl
 Palpation adequate for annual breast exam. 264, Sep, nl
 Radiation lesion may resemble recurrent Ca. 281, Nov, nl
 Radiotherapy's benefit for breast cancer dubious. 266, Sep, nl
 What treatment alternatives for minimal breast cancer? 107, Oct, oa
BREAST RECONSTRUCTION
 What you should know about reconstructive breast surgery. 177, Nov, oa
BREECH PRESENTATION (see LABOR PRESENTATION)
BROMELINS
 Immunologic infertility: Which approaches are best? 153, Sep, oa
BROMOCRIPTINE
 Does prolactin affect the bone? 15, Jul, et
 How to induce ovulation. 201, 213, 214, Oct, s
 Prescribing FDA-approved drugs in nonapproved ways. 28, Aug, oa
BRONCHOSCOPE
 Little-known ob-gyn milestone—Mendelson on gastric aspiration. 101, Oct, oa
CAFFÉINE
 Consider the cervical factor in reproduction. 196, Aug, oa
CALCIUM
 Nonhormonal approach to osteoporosis debated. 280, Nov, nl
CANCER (see CARCINOMA; NEOPLASMS; SPECIFIC ORGAN NEOPLASMS)
CAPILLARY PERMEABILITY
 Recognizing and treating toxic shock. 49, Jul, oa
CARBOHYDRATES
 Diagnostic clues from vaginal odors. 200, 201, Nov, oa
 New diet advice for diabetics? 15, Aug, et
 New diet advice for diabetics? Author's reply. 15, Aug, et
CARBON DIOXIDE
 How to select a cryosurgical unit. 101, T84, oa
 New instruments and techniques for hysteroscopy. 71, 72, T84, oa
CARCINOGENS
 Safe medications during pregnancy. 53, Nov, oa
CARCINOMA
 Breast disease—first line of defense. 11, Sep, ed
 Cervical cancer risk for teenage smokers. 238, Oct, nl
 Choosing the best urinary diversion for gyn patients. 253, Nov, oa
 Colposcopic patterns of papillomavirus infection. 107, 109, 112, 115, Sep, oa
 Detecting endometrial cancer and precursor lesions. 231, Sep, s
 Evaluating male partners of condyloma patients. 184, 187, 193, Oct, oa
 Examining patients who have had conization or hysterectomy. 108, 110, Dec, oa
 Herpesviruses: why control is difficult. 72, Aug, oa
 How tumor growth rate affects outcome. 264, Sep, nl
 HPV and cervical cancer. 239, Oct, nl
 Lumps: When is close follow-up appropriate? 204, 205, 206, 209, Sep, oa
 Lymph node x-rays as possible prognostic indicators. 237, Oct, nl
 Ovarian Ca—more on cytoreduction. 68, Nov, oa
 Ovarian germ cell tumors. 29, Oct, et
 Over-40 OC users' risk for cancer down. 239, Oct, nl
 Palpation adequate for annual breast exam. 264, Sep, nl
 Pill's many noncontraceptive benefits. 143, 148, 150, Oct, oa
 Prescribing FDA-approved drugs in nonapproved ways. 36, 40, Aug, oa
 Problems linked to uterine myomas. 271, 272, Nov, s
 Radiotherapy's benefit for breast cancer dubious. 266, Sep, nl
 Scanning the pelvis for neoplasia. 115, Dec, oa
 Small-cell cancer of the cervix. 119, Oct, pp
 Strategy for managing breech presentation. 18, Jul, et
 Strategy for managing breech presentation. Author's reply. 20, Jul, et
 Tracking an elusive entity—microinvasive cervical cancer. 151, Aug, s
 What treatment alternatives for minimal breast cancer? 107, Oct, oa
 When the pregnant patient has an abnormal Pap smear. 86, 88, 92, Aug, oa
CARCINOMA IN SITU
 Detecting endometrial cancer and precursors. 232, 233, 234, 239, Sep, s
 Why are cervical Ca rates rising in younger women? 245, Dec, nl
 What treatment alternatives for minimal breast cancer? 107, Oct, oa
CARCINOMA, OAT CELL
 Small-cell cancer of the cervix. 120, 126, Oct, pp
CARCINOMA, SQUAMOUS CELL
 Cervical condyloma and CIN: How are they related? 128, Sep, oa
 Small-cell cancer of the cervix. 119, 120, 121, 125, 126, Oct, pp
CARDIOVASCULAR DISEASES (see also MYOCARDIAL DISEASES)
 Cardiac arrhythmias in pregnant women. 159, 164, 166, 170, Jul, oa
 Flexible prescribing of estrogens. 155, 159, Nov, oa
 LDL cholesterol linked to high-progestin OCs. 220, Aug, nl
 Pill's many noncontraceptive benefits. 136, 150, Oct, oa
CARDIOVASCULAR SYSTEM
 Doppler ultrasound detects patent ductus arteriosus early. 221, Aug, nl

Tracking tubal sterilization deaths. 223.
Aug, nl

CATHETERIZATION

How to avoid or minimize urologic injuries in surgery. 213, Jul, oa
Progress in managing hydronephrosis in utero. 47, 57, 66, Oct, oa
Recognizing and treating toxic shock. 49.
Jul, oa

CEFAZOLIN

Hysterectomy costs cut by prophylaxis. 237, 238, Oct, nl

CENTERS FOR DISEASE CONTROL

CDC urges vaccinating adults as rubella in children disappears. 246, Dec, nl
Condyloma concern multiplies over a 15-year period. 221, Aug, nl

Dealing with viral hepatitis during pregnancy. 43, 48, Sep, oa
Incidence of ectopics rising in US. 240, Oct, nl

Pill's many noncontraceptive benefits. 137, 140, 143, 148, Oct, oa
Recognizing and treating toxic shock. 43, Jul, oa

Tracking tubal sterilization deaths. 222, Aug, nl

CEPHALOSPORINS

Recognizing and treating toxic shock. 55, Jul, oa

CEREBRAL VASOSPASM

Minimizing side effects from β -adrenergic tocolytics. 172, Oct, oa
CERVICITIS

Update from San Francisco: the 1983 AFS report. 176, 180, Sep, oa

CERVIX

Amniocentesis and the incompetent cervix. 16, Jul, et

Cervical condyloma and CIN: How are they related? 116, Sep, oa

Ensuring optimum outcome for postdate pregnancy. 199, 200, Dec, s

Examining patients who have had conization or hysterectomy. 99, Dec, oa

Fertility problems of DES daughters. 197, Aug, oa

Fitting a diaphragm. 181, Aug, oa

How to insert an IUD. 163, Sep, cd

Immunologic infertility: Which approaches are best? 153, Sep, oa

Managing missed abortion and antepartum fetal death. 20, 22, Sep, pr

Meeting the challenge of cervical cone biopsy. 85, Dec, oa

Risk factors for cervical injury in suction D & C. 280, Nov, nl

Techniques for following irradiated patients. 103, 104, 106, Nov, oa

Tracking an elusive entity—microinvasive cervical cancer. 151, Aug, s

When the pregnant patient has an abnormal Pap smear. 77, Aug, oa

CERVIX DISEASES

Cervical condyloma and CIN: How are they related? 116, Sep, oa

Colposcopic patterns of papillomavirus infection. 107, Sep, oa

CERVIX INCOMPETENCE

Amniocentesis and the incompetent cervix. 16, Jul, et
Fertility problems of DES daughters. 199, Aug, oa

CERVIX MUCUS

Consider the cervical factor in reproduction. 187, Aug, oa

Diagnostic clues from vaginal odors. 201, Nov, oa

How to induce ovulation. 207, 208, Oct, s
Immunologic infertility: Which approaches are best? 143, 148, 153, 155, Sep, oa

CERVIX NEOPLASMS

Cervical cancer risk for teenage smokers. 238, Oct, nl

Cervical condyloma and CIN: How are they related? 116, Sep, oa

Colposcopic patterns of papillomavirus infection. 107, 115, Sep, oa

Examining patients who have had conization or hysterectomy. 99, Dec, oa

How to select a cryosurgical unit. 101, T84, oa

HPV and cervical cancer. 239, Oct, nl

Scanning the pelvis for neoplasia. 115, 117, Dec, oa

Small-cell cancer of the cervix. 119, Oct, ppc

Tracking an elusive entity—microinvasive cervical cancer. 151, Aug, s

Why are cervical CA rates rising in younger women? 245, Dec, oa

CESAREAN SECTION

Choosing anesthesia for high-risk ob patients. 76, 80, 83, Sep, oa

Coping successfully with cord prolapse. 199, 201, 208, Jul, oa

Dealing with viral hepatitis during pregnancy. 35, 36, Sep, oa

Expanding the role of β -sympathomimetic drugs in obstetric emergencies. 126, 128, 133, 136, 139, 140, Jul, oa

Fetal distress indicating abruptio placentae. 16, Oct, emf

Guide to sinusoidal FHR patterns. 96, 100, Aug, oa

How to treat nonobstetric abdominal pain in pregnancy. 47, Aug, oa

Loss of movement dictates evaluation. 21, Oct, emf

Management of amnionitis. 23, Nov, pr

Problems linked to uterine myomas. 273, 276, Nov, s

Strategy for managing breech presentation. 18, Jul, et

Strategy for managing breech presentation. Author's reply. 20, Jul, et

When liver disease complicates pregnancy. 60, 73, Sep, ppc

When the patient has placenta previa. 18, 20, Dec, pr

CHARTS

Tricks of the trade in displaying data. 99, 100, Sep, oa

CHEMILUMINESCENCE

Chemiluminescence as a biologic marker. 47, T84, oa

CHILD ABUSE

Pediatric gyn trauma. 155, Jul, oa

CHLAMYDIA INFECTIONS

Update from San Francisco: the 1983 AFS report. 176, Sep, oa

CHOLECYSTITIS

How to treat nonobstetric abdominal pain in pregnancy. 48, Aug, oa

Nonobstetric abdominal pain in pregnancy: What's the cause? 71, 72, 75, 76, Jul, oa

CHOLESTASIS, INTRAHEPATIC

When liver disease complicates pregnancy. 59, 64, Sep, ppc

CHOLESTEROL

Nonobstetric abdominal pain in pregnancy: What's the cause? 71, 72, Jul, oa

CHORIONIC VILLI

Chorionic villi sampling: its promise and its problems. A source of fetal cells. 31, T84, oa

Chorionic villi sampling: its promise and its problems. Potential for improving fetal treatment. 38, T84, oa

Old questions about a new procedure. 3, 6, T84, ed

CHROMOSOMES

Gene linkage and prenatal diagnosis. 85, Oct, oa

CIRCADIAN RHYTHM

Fetal activity: measure of well-being. 214, 215, Sep, oa

CLASTOGENS

Safe medications during pregnancy. 53, Nov, oa

CLOMIPHENE

How to induce ovulation. 199, 206, 207, 212, 213, 214, Oct, s

Prescribing FDA-approved drugs in nonapproved ways. 28, Aug, oa

Update from San Francisco: the 1983 AFS report. 189, Sep, oa

CLONE CELLS

DNA probes for muscular dystrophy. 245, Dec, nl

CLONING, MOLECULAR

How recombinant DNA technology may transform medicine and industry. 203, Aug, oa

COCAINE

Obstetric use of local anesthetics. 46, Dec, oa

COLON

Guidelines for exploring the abdomen. 163, 166, Dec, oa

COLPOSCOPY

Colposcopic patterns of papillomavirus infection. 107, Sep, oa

Consider the cervical factor in reproduction. 191, 194, Aug, oa

Evaluating male partners of condyloma patients. 183, Oct, oa

Examining patients who have had conization or hysterectomy. 99, Dec, oa

Technique for following irradiated patients. 103, Nov, oa

Tracking an elusive entity—microinvasive cervical cancer. 151, Aug, s

Update on colposcopes and their accessories. 85, T84, oa

When the pregnant patient has an abnormal Pap smear. 77, Aug, oa

COMPARTMENT SYNDROMES

Contraindications to the gravity suit. 15, Sep, et

Contraindications to the gravity suit. Author's reply. 15, Sep, et

COMPUTERS

Computer applications in the ob-gyn office. 71, Dec, oa

Using the computer to estimate fetal weight. 25, T84, oa

CONDOMS

Evaluating male partners of condyloma patients. 185, 195, Oct, oa

CONDYLOMA ACUMINATUM

Cervical condyloma and CIN: How are they related? 116, Sep, oa

Colposcopic patterns of papillomavirus infections. 107, 108, 112, Sep, oa

Condyloma concern multiplies over a 15-year period. 221, Aug, nl

Evaluating male partners of condyloma patients. 183, Oct, oa

CONIZATION

Consider the cervical factor in reproduction. 191, 194, Aug, oa

Examining patients who have had conization or hysterectomy. 99, Dec, oa

Meeting the challenge of cervical cone biopsy. 85, Dec, oa

Tracking an elusive entity—microinvasive cervical cancer. 152, Aug, s

When the pregnant patient has an abnormal Pap smear. 77, 88, 92, Aug, oa

CONTRACEPTIVES

Fitting a diaphragm. 181, Aug, oa

How to insert an IUD. 163, Sep, ed

CONTRACEPTIVES, ORAL

LDL cholesterol linked to high-progestin OCs. 220, Aug, nl

Over-40 OC users' risk for cancer down. 239, Oct, nl

Pill's many noncontraceptive benefits. 136, Oct, oa

Prescribing FDA-approved drugs in nonapproved ways. 27, 32, Aug, oa

Problems linked to uterine myomas. 276, 277, Nov, s

CONTRACEPTIVES, POSTCOITAL

Prescribing FDA-approved drugs in nonapproved ways. 35, 36, Aug, oa

CONTRACTION STRESS TEST

Protocol for the nipple-stimulation CST. 157, Oct, oa

CONTROL GROUP

What matching achieves. 171, Nov, oa

CONVULSIONS

Guide to MgSO₄ therapy for PIH. 65, 66, Dec, cd

COOMBS' TEST

Immunologic infertility: Which approaches are best? 150, Sep, oa

Managing Rh immunization. 33, 36, Oct, pr

CORPUS LUTEUM

Update from San Francisco: the 1983 AFS

DECEMBER 1983 221

Brief Summary**CEFOBID®**

(cefoperazone sodium)

CONTRAINDICATIONS: CEFOBID is contraindicated in patients with known allergy to the cephalosporin-class of antibiotics.**WARNINGS:** BEFORE THERAPY WITH CEFOBID IS INSTITUTED CAREFUL INQUIRY SHOULD BE MADE CONCERNING WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEPHALOSPORINS, PENICILLINS OR OTHER DRUGS. THIS PRODUCT SHOULD BE GIVEN CAUTIOUSLY TO PENICILLIN-SENSITIVE PATIENTS. ANTIBIOTICS SHOULD BE ADMINISTERED WITH CAUTION TO ANY PATIENT WHO HAS DEMONSTRATED SOME FORM OF ALLERGY, PARTICULARLY TO DRUGS. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE THE USE OF SUBCUTANEOUS EPINEPHRINE AND OTHER EMERGENCY MEASURES.**PSEUDOMEMBRANOUS COLITIS HAS BEEN REPORTED WITH THE USE OF CEPHALOSPORINS (AND OTHER BROAD-SPECTRUM ANTIBIOTICS). THEREFORE, IT IS IMPORTANT TO CONSIDER ITS DIAGNOSIS IN PATIENTS WHO DEVELOP DIARRHEA IN ASSOCIATION WITH ANTI-BIOTIC USE.****PRECAUTIONS:** Although transient elevations of the BUN and serum creatinine have been observed, CEFOBID alone does not appear to cause significant nephrotoxicity. However, concomitant administration of aminoglycosides and other cephalosporins should be avoided.

CEFOBID is rapidly excreted in bile. The serum half-life of CEFOBID is increased 2-4 fold in patients with hepatic disease and/or biliary obstruction. In general, total daily dosage above 4 g should not be necessary in such patients. If higher dosages are used, serum concentrations should be monitored.

Because renal excretion is not the main route of elimination of CEFOBID (see CLINICAL PHARMACOLOGY), patients with renal failure require no adjustment in dosage when usual doses are administered. When high doses of CEFOBID are used, concentrations of drug in the serum should be monitored periodically. If evidence of accumulation exists, dosage should be decreased accordingly.

The half-life of CEFOBID is reduced slightly during hemodialysis. Thus, dosing should be scheduled to follow a dialysis period. In patients with both hepatic dysfunction and significant renal disease, CEFOBID dosage should not exceed 1-2 g daily without close monitoring of serum concentrations.

As with other antibiotics, Vitamin K deficiency has occurred rarely in patients treated with CEFOBID. Those at risk include patients with a history of tritonitis, sarcoidosis, and sarcoidosis (e.g., hepatic fibrosis), alcoholism, and patients with prolonged hypocoagulable states (e.g., administered either intravenously or via a naso-gastric tube). Prothrombin time should be monitored in these patients and exogenous Vitamin K administered as indicated.

A disulfiram-like reaction characterized by flushing, sweating, headache, and tachycardia has been reported when alcohol (beer, wine) was ingested within 72 hours after CEFOBID administration. Patients should be cautioned about the ingestion of alcoholic beverages following the administration of CEFOBID. A similar reaction has been reported with other cephalosporins.

Prolonged use of CEFOBID may result in the overgrowth of nonspirochetal organisms. Careful observation of the patient is essential.

CEFOBID should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.

Drug Laboratory Test Interactions

A false-positive reaction for glucose in the urine may occur with Benedict's or Fehling's solution.

Carcinogenesis, Mutagenesis, Impairment of FertilityThe maximum duration of CEFOBID animal toxicity studies is six months. In none of the *in vivo* or *in vitro* genetic toxicology studies did CEFOBID show any mutagenic potential at either the chromosomal or subchromosomal level. CEFOBID produced no impairment of fertility and had no effects on general reproductive performance or fetal development when administered subcutaneously at daily doses up to 500 to 1000 mg/kg prior to and during mating, and to pregnant female rats during gestation. These doses are 10 to 20 times the estimated usual single clinical dose.**Usage in Pregnancy: Pregnancy Category B.** Reproduction studies have been performed in mice, rats, and monkeys at doses up to 10 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to CEFOBID. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.**Usage in Nursing Mothers:** Only low concentrations of CEFOBID are excreted in human milk. Although CEFOBID passes poorly into breast milk of nursing mothers, caution should be exercised when CEFOBID is administered to a nursing woman.**Pediatric Use:** Safety and effectiveness in children have not been established.**ADVERSE REACTIONS:** In clinical studies the following adverse effects were observed and were considered to be related to CEFOBID therapy or uncertain etiology.**Hypersensitivity:** As with all cephalosporins, hypersensitivity manifested by skin reactions (1 patient in 45), drug fever (1 in 260), or a change in Coombs' test (1 in 60) has been reported. These reactions are more likely to occur in patients with a history of allergies, particularly to penicillin.**Hematology:** As with other beta-lactam antibiotics, reversible neutropenia may occur with prolonged administration. Slight decreases in neutrophil count (1 patient in 50) have been reported. Decreased hemoglobin (1 in 20) or hematocrits (1 in 20) have been reported, which is consistent with published literature on other cephalosporins. Transient eosinophilia has occurred in 1 patient in 10.**Hepatic:** Of 1285 patients treated with cefoperazone in clinical trials one patient with a history of liver disease developed significantly elevated liver function enzymes during CEFOBID therapy. Clinical signs and symptoms of non-specific hepatitis accompanied these increases. After CEFOBID therapy was discontinued, the patient's enzymes returned to pre-treatment levels and the symptomatology resolved. As with other antibiotics that achieve high bile levels, transient elevations of serum liver enzymes have been observed in 5-10% of patients receiving CEFOBID therapy. The relevance of these findings, which were not accompanied by overt signs or symptoms of hepatic dysfunction, has not been established.**Gastrointestinal:** Diarrhea or loose stools has been reported in 1 in 30 patients. Most of these experiences have been mild or moderate in severity and self-limiting in nature. In all cases, these symptoms responded to symptomatic therapy or ceased when cefoperazone therapy was stopped. Nausea and vomiting have been reported rarely.

Symptoms of pseudomembranous colitis can appear during or for several weeks subsequent to antibiotic therapy (see WARNINGS).

Renal Function Tests: Transient elevations of the BUN (1 in 16) and serum creatinine (1 in 48) have been noted.**Local Reactions:** CEFOBID is well tolerated following intramuscular administration. Occasionally, transient pain (1 in 140) may follow administration by this route. When CEFOBID is administered by intravenous infusion some patients may develop phlebitis (1 in 120) at the infusion site.**For Intravenous or Intramuscular Use****EDITORIAL INDEX**

report. 187, Sep, oa

CORTICOTROPIN

Managing acute adrenal insufficiency. 113, Jul, oa

COST-BENEFIT ANALYSIS

Hysterectomy costs cut by prophylaxis. 237, 238, Oct, nl

COUNSELING

Helping a patient surrender her child for adoption. 30, 32, Dec, oa

How to manage the victim of rape. 259, Sep, oa

CREATININE

Nonobstetric abdominal pain in pregnancy: What's the cause? 77, 78, Jul, oa

CRIME

How to manage the victim of rape. 253, Sep, oa

PMS—looking for new answers to an old problem. 121, Aug, oa

CRYOTHERAPY

Cervical condyloma and CIN: How are they related? 132, Sep, oa

Evaluating male partners of condyloma patients. 193, Oct, oa

How to select a cryosurgical unit. 101, T84, oa

CULDOCENTESIS

When you suspect ectopic pregnancy. 93, 94, 109, Jul, oa

CYTODIAGNOSIS

Detecting endometrial cancer and precursor lesions. 231, Sep, s

CYTogenetics

Gene linkage and prenatal diagnosis. 86, 87, Oct, oa

CYTologic TECHNIQUES

Tracking an elusive entity—microinvasive cervical cancer. 153, 154, 159, Aug, s

CYTOLogy

Aspiration smears for breast lesion diagnosis. 266, Sep, nl

Cervical condyloma and CIN: How are they related? 116, Sep, oa

Colposcopic patterns of papillomavirus infection. 107, Sep, oa

Technique for following irradiated patients. 103, Nov, oa

CYTomegaloviruses

Dealing with hepatitis during pregnancy. 29, 33, Sep, oa

Herpesviruses: why control is difficult. 61, 62, 63, 68, 72, 74, Aug, oa

CYTOTOXINS

Evaluating male partners of condyloma patients. 193, Oct, oa

DATA COLLECTION

Tricks of the trade in displaying data. 87, Sep, oa

DATA TABLES

Tricks of the trade in displaying data. 87, 88, Sep, oa

DEATH

Neonatal death: caring for the parents. 24, Sep, pr

DEFENSE MECHANISMS

Helping a patient surrender her child for adoption. 29, Dec, oa

DELIVERY

Choosing anesthesia for high-risk ob patients. 75, Sep, oa

Coping successfully with cord prolapse. 198, Jul, oa

Ensuring optimum outcome for postdate pregnancy. 206, 207, 210, Dec, s

Expanding the role of β -sympathomimetic drugs in obstetric emergencies. 128, 133, 136, 139, 140, Jul, oa

Helping a patient surrender her child for adoption. 32, 33, Dec, oa

How worthwhile are membrane stripping and amniotomy? 173, Dec, oa

Little-known ob-gyn milestone—Mendelson on gastric aspiration. 95, Oct, oa

Management of amniotic. 22, 23, Nov, pr

Managing missed abortion and antepartum fetal death. 17, Sep, pr

Managing placental abruption. 23, Dec, pr

Managing polyhydramnios. 21, Aug, pr

Preps and enemas—keep or discard? 241, Nov, oa

Progress in managing hydronephrosis. 52, 60, Oct, oa

Spotting and treating intrauterine growth retardation. 23, Nov, pr

Strategy for managing breech presentation. 16, 18, Jul, et

Strategy for managing breech presentation. Author's reply. 18, Jul, et

When your patient has pregnancy-induced hypertension. 42, Oct, pr

DENSITOMETRY

Better way to screen for osteoporosis. 116, 118, 119, 123, 124, 127, Nov, oa

DEPRESSION

Helping a patient surrender her child for adoption. 37, 38, 40, Dec, oa

PMS—looking for new answers to an old problem. 112, 116, Aug, oa

DEXAMETHASONE

How to induce ovulation. 212, 213, Oct, s

Prescribing FDA-approved drugs in nonapproved ways. 40, Aug, oa

DEXTRANS

New instruments and techniques for hysteroscopy. 71, 72, T84, oa

DIABETES

Pills's many noncontraceptive benefits. 136, Oct, oa

DIABETES, GESTATIONAL

Managing polyhydramnios. 25, Aug, pr

New for high-risk ob—the maternal-fetal ICU. 172, Aug, oa

When liver disease complicates pregnancy. 59, 60, Sep, ppc

DIABETIC DIET

New diet advice for diabetics? 15, Aug, et

New diet advice for diabetics? Author's reply. 15, Aug, et

DIAGNOSIS (see PRENATAL CARE)**DIAGNOSIS, COMPUTER-ASSISTED**

Computer applications in the ob-gyn office. 72, 77, 78, Dec, oa

DIAGNOSTIC ERRORS

Cervical condyloma and CIN: How are they related? 117, 118, 121, Sep, oa

ROERIG A division of Pfizer Pharmaceuticals
New York, New York 10017

Detecting endometrial and precursor lesions. 239, 240, Sep, s

Ovarian germ cell tumors. 29, Oct, et

Radiation lesion may resemble recurrent Ca. 261, Nov, n

Tracking an elusive entity—microinvasive cervical cancer. 153, 154, 160, Aug, s

DIAGNOSTIC TESTS

Better way to screen for osteoporosis. 116, Nov, oa

Chorionic villi sampling: its promise and its problems. A source of fetal cells. 31, T84, oa

Chorionic villi sampling: its promise and its problems. Potential for improving fetal treatment. 38, T84, oa

Colposcopic patterns of papillomavirus infection. 107, Sep, oa

Consider the cervical factor in reproduction. 87, Aug, oa

Evaluating male partners of condyloma patients. 190, Oct, oa

Lymph node x-rays as possible prognostic indicators. 237, Oct, n

Management of amnionitis. 19, Nov, pr

Managing polyhydramnios. 17, Aug, pr

Managing Rh immunization. 33, 34, Oct, pr

New assay for confirming fetal NTDs. 247, Dec, n

New for high-risk ob—the maternal-fetal ICU. 171, 172, 178, Aug, oa

New instruments and techniques for hysteroscopy. 67, T84, oa

NMR—new for ob-gyn imaging. 9, T84, oa

Nonobstetric abdominal pain in pregnancy: What's the cause? 77, 78, Jul, oa

Old questions about a new procedure. 3, T84, ed

Ovarian Ca—more on cytoreduction. 68, Nov, oa

Problems linked to uterine myomas. 270, 271, 272, Nov, s

Progress in managing hydronephrosis in utero. 47, Oct, oa

Scanning the pelvis for neoplasia. 115, Dec, oa

Small-cell cancer of the cervix. 119, 121, 125, Oct, ppc

Thyroid storm need not be lethal. 136, 137, Aug, oa

Tracking an elusive entity—microinvasive cervical cancer. 153, 154, 159, Aug, s

What treatment alternatives for minimal breast cancer? 107, Oct, oa

What's available in EFM equipment. 17, T84, oa

When you suspect ectopic pregnancy. 91, 92, 93, Jul, oa

Your pregnant patient's rash: Is it PUPP syndrome? 153, Dec, oa

DIALYSIS, PERITONEAL

Thyroid storm need not be lethal. 146, Aug, oa

DIAPHRAGMATIC HERNIA

AMA group weighs benefits of fetal surgery. 247, Dec, n

DIET

Diet for preterm infants. 237, Oct, n

Nonhormonal approach to osteoporosis debated. 280, Nov, n

When your patient has pregnancy-induced hypertension. 39, Oct, pr

DIET THERAPY

New diet advice for diabetics? 15, Aug, et

DIETHYLSTILBESTROL

Fertility problems of DES daughters. 197, Aug, oa

DIGITALIS

Cardiac arrhythmias in pregnant women. 163, 164, 166, Jul, oa

Little-known ob-gyn milestone—Mendelson on gastric aspiration. 101, Oct, oa

Which therapeutic agents for cardiac arrhythmias? 195, Jul, oa

DIGOXIN

Cardiac arrhythmias in pregnant women. 159, 160, Jul, oa

Which therapeutic agents for cardiac arrhythmias? 195, Jul, oa

DILATION AND CURETTAGE

Examining patients who have had conception or hysterectomy. 99, Dec, oa

Managing missed abortion and antepartum fetal death. 17, Sep, pr

Meeting the challenge of cervical cone biopsy. 88, Dec, oa

When you suspect ectopic pregnancy. 98, Jul, oa

DIPHOSPHONATES

Nonhormonal approach to osteoporosis debated. 280, Nov, n

DIPLOIDY

Cervical condyloma and CIN: How are they related? 118, Sep, oa

DISCRIMINATION

Work and pregnancy: guidelines needed. 9, Aug, ed

DISSEMINATED INTRAVASCULAR COAGULATION

Managing missed abortion and antepartum fetal death. 17, 20, Sep, pr

When liver disease complicates pregnancy. 68, Sep, ppc

DIURETICS

PMS—looking for new answers to an old problem. 109, Aug, oa

DNA

Cervical condyloma and CIN: How are they related? 118, 129, Sep, oa

Chorionic villi sampling: its promise and its problems. A source of fetal cells. 32, 33, 38, T84, oa

DNA probes for muscular dystrophy. 245, Dec, n

Herpesviruses: why control is difficult. 61, Aug, oa

Intricacies of spermatogenesis. 230, 231, Nov, oa

DNA, RECOMBINANT

How recombinant DNA technology may transform medicine and industry. 203, Aug, oa

DNA RESTRICTION ENZYMES

How recombinant DNA technology may transform medicine and industry. 203, 204, Aug, oa

DNA STRUCTURE

Herpesviruses: why control is difficult. 61, Aug, oa

DNA, VIRAL

How recombinant DNA technology may transform medicine and industry. 209, Aug, oa

DOPAMINE

Recognizing and treating toxic shock. 50, 53, Jul, oa

DRUG ABUSE

Effects of marijuana on reproduction. 217, Oct, oa

DRUG ADMINISTRATION

Dos and don'ts of treating preeclampsia and eclampsia with MgSO₄. 164, 165, 166, Oct, oa

DRUG EFFECTS

Choosing anesthesia for high-risk ob patients. 82, 83, 84, Sep, oa

Does prolactin affect the bone? 15, Jul, et

Dos and don'ts of treating preeclampsia and eclampsia with MgSO₄. 163, 164, 166, 167, Oct, oa

Expanding the role of β -sympathomimetic drugs in obstetric emergencies. 122, Jul, oa

Flexible prescribing of estrogens. 137, Nov, oa

Managing acute adrenal insufficiency. 113, Jul, oa

Minimizing side effects from β -adrenergic tocolytics. 169, Oct, oa

Safe medications during pregnancy. 40, Nov, oa

Which therapeutic agents for cardiac arrhythmias? 187, Jul, oa

DRUG LABELING

Prescribing FDA-approved drugs in nonapproved ways. 27, Aug, oa

DRUG RESISTANCE

Single source found for six cases of drug-resistant TB. 246, 247, Dec, n

DRUG THERAPY

Cardiac arrhythmias in pregnant women. 158, Jul, oa

Cervical condyloma and CIN: How are they related? 134, Sep, oa

Classic symptoms may not indicate UTI. 222, Aug, n

Consider the cervical factor in reproduction. 194, 195, 196, Aug, oa

Does prolactin affect the bone? 15, Jul, et

Dos and don'ts of treating preeclampsia with MgSO₄. 163, Oct, oa

Evaluating male partners of condyloma patients. 193, Oct, oa

Exogenous estrogens reverse some age-related changes. 238, Oct, n

Expanding the role of β -sympathomimetic drugs in obstetric emergencies. 122, Jul, oa

GnRH deficiency: tailor therapy according to severity. 280, Nov, n

Guide to MgSO₄ therapy for PIH. 65, Dec, id

Herpesviruses: why control is difficult. 72, 74, Aug, oa

How to induce ovulation. 199, Oct, s

How to treat nonobstetric abdominal pain in pregnancy. 47, Aug, oa

Hysterectomy costs cut by prophylaxis. 237, 238, Oct, n

Immunologic infertility: Which approaches are best? 155, 156, Sep, oa

Little-known ob-gyn milestone—Mendelson on gastric aspiration. 101, Oct, oa

Lumps: When is close follow-up appropriate? 196, Sep, oa

Managing acute adrenal insufficiency. 113, Jul, oa

Minimizing side effects from β -adrenergic tocolytics. 169, Oct, oa

Ovarian Ca—more on cytoreduction. 81, 84, Nov, oa

PMS—looking for new answers to an old problem. 102, Aug, oa

PPNG infection controlled in LA. 223, Aug, n

Prescribing FDA-approved drugs in nonapproved ways. 27, Aug, oa

Recognizing and treating toxic shock. 50, 53, 54, 55, Jul, oa

Small-cell cancer of the cervix. 119, 131, Oct, ppc

Thyroid storm need not be lethal. 135, Aug, n

What treatment alternatives for minimal breast cancer? 113, 116, Oct, oa

When to refer psychiatric problems. 250, Nov, oa

Which therapeutic agents for cardiac arrhythmias? 187, Jul, oa

Your pregnant patient's rash: Is it PUPP syndrome? 153, Dec, oa

DRUGS

Expanding the role of β -sympathomimetic drugs in obstetric emergencies. 122, Jul, oa

Prescribing FDA-approved drugs in nonapproved ways. 27, Aug, oa

Safe medications during pregnancy. 40, Nov, oa

DUODENUM

Guidelines for exploring the abdomen. 163, Dec, oa

ECLAMPSIA (see PREGNANCY TOXEMIAS)

EDEMA

PMS—looking for new answers to an old problem. 104, 109, Aug, oa

When your patient has pregnancy-induced hypertension. 36, Oct, pr

EDUCATION, MEDICAL

Computer applications in the ob-gyn office. 78, Dec, oa

ELECTRIC COUNTERSHOCK

Cardiac arrhythmias in pregnant women. 166, Jul, oa

Which therapeutic agents for cardiac arrhythmias? 196, Jul, oa

ELECTROCARDIOGRAPHY

Cardiac arrhythmias in pregnant women. 159, 166, 172, 174, 180, Jul, oa

What's available in EFM equipment. 20, T84, oa

HYPRHO®-D

Rh_O (D) Immune Globulin (Human)

Summary of Prescribing Information

DESCRIPTION Rh_O(D) Immune Globulin (Human) — HypRho®-D is a sterile solution of immune globulin containing antibodies to Rh_O(D) prepared from human venous plasma collected from carefully screened donors. It contains 16.5 ± 1.5% protein stabilized with 0.3 M glycine and preserved with 1:10,000 thimerosal (a mercury derivative). The pH is adjusted with sodium carbonate. HypRho-D has been titrated against and the potency found equal to or greater than that of the U.S. Food and Drug Administration Reference Rh_O(D) Immune Globulin (Human). One vial has been shown to effectively suppress the immunizing potential of 15 ml of Rh_O(D) positive or D⁺ positive packed red blood cells.

This product was prepared from large pools of human venous plasma. Each individual unit of plasma has been found nonreactive for hepatitis B surface antigen (HBsAg) using a U.S. Federally approved test of at least third-generation sensitivity.

INDICATIONS AND USAGE

Pregnancy and Other Obstetric Conditions

HypRho-D is recommended for prevention of Rh hemolytic disease of the newborn by immunization of the Rh_O(D) negative, D⁺ negative mother within 72 hours after birth of a Rh_O(D) positive or D⁺ positive infant, providing the following criteria are met:

1. The mother must be Rh_O(D) and D⁺ negative and must not already be sensitized to the Rh_O(D) factor.

2. Her child must be Rh_O(D) positive or D⁺ positive, and should have a negative direct Coombs test. A positive direct Coombs test may be caused by antibodies other than Rh_O(D) and while this does not contraindicate therapy with HypRho-D, it should be investigated. A positive direct Coombs test due to anti-Rh_O(D) is a contraindication to the use of HypRho-D.

Even though Rh hemolytic disease of the newborn is less frequent when there is ABO incompatibility between the Rh_O(D) negative mother and the Rh_O(D) positive fetus, protection against Rh_O(D) sensitization may be incomplete, and treatment of the mother with HypRho-D is indicated in such cases.

The administration of Rh_O(D) Immune Globulin within 72 hours of a full-term delivery of an infant to a Rh_O(D) negative, D⁺ negative mother at risk reduces the incidence of Rh isoimmunization from 12-13% to 1-2%. The 1-2% treatment failures are probably due to isoimmunization occurring during the latent part of pregnancy or following delivery. Bowman, et al have reported that the incidence of isoimmunization can be further reduced from approximately 1.6% to less than 0.1% by administering Rh_O(D) Immune Globulin in two doses, one antenatal at 28 weeks gestation and another following delivery.

HypRho-D should also be administered within 72 hours to all nonimmunized Rh_O(D) negative, D⁺ negative women who have undergone spontaneous or induced abortion, following ruptured tubal pregnancy or following amniocentesis unless the blood type of the fetus is known to be Rh_O negative, D⁺ negative. If the fetal blood type is unknown, one must assume that it is Rh_O(D) positive and Rh_O(D) Immune Globulin (Human) — HypRho-D should be administered to the mother.

TRANSFUSION HypRho-D may be used to prevent isoimmunization in Rh_O(D) negative, D⁺ negative individuals who have been transfused with Rh_O(D) positive or D⁺ positive red blood cells or blood components containing red blood cells.

CONTRAINdications

HypRho-D is contraindicated for use in:

1. A Rh_O(D) positive or D⁺ positive individual.

2. A Rh_O(D) negative or D⁺ negative individual previously sensitized to the Rh_O(D) or D antigen.

ADVERSE REACTIONS Reactions to Rh_O(D) Immune Globulin (Human) are infrequent in Rh_O(D) negative, D⁺ negative individuals and consist primarily of slight soreness at the site of injection and slight temperature elevation. While sensitization to repeated injections of human immune globulin is extremely rare, it has occurred. Elevated bilirubin levels have been reported in some individuals receiving multiple doses of Rh_O(D) Immune Globulin (Human) following mismatched transfusions. This is believed to be due to a relatively rapid rate of foreign red cell destruction.

No instances of transmission of hepatitis have been reported from the use of human immune globulin prepared by the fractionation methods employed at Cutter Laboratories, Inc.

PRECAUTIONS

NEVER ADMINISTER HypRho-D INTRAVENOUSLY.

NEVER ADMINISTER TO THE NEONATE.

WARNINGS

1. Solutions which have been frozen should not be used.

2. Partially used vials must be discarded.

PRE-ADMINISTRATION LABORATORY PROCEDURES

Using a broad-spectrum complement fixation test, i.e., a test capable of detecting IgM and IgG incomplete antibodies, check the individual's serum for Rh_O(D) antibody to ascertain that the patient has not been already sensitized to the Rh_O(D) blood factor.

INJECTION PROCEDURE

A. Single Vial Dose

INJECT ENTIRE CONTENTS OF THE VIAL INTO THE INDIVIDUAL INTRAMUSCULARLY. DO NOT INJECT INTRAVENOUSLY. DO NOT INJECT NEONATE.

B. Multiple Vial Dose

1. Calculate the number of vials of HypRho-D to be given.

2. The total volume of HypRho-D can be given in divided doses at different sites at one time or the total dose may be divided and injected at intervals provided the total dosage is given within 72 hours of the fetal-maternal hemorrhage or transfusion. Using sterile technique, withdraw the entire contents of the calculated number of vials and inject them intramuscularly into the patient.

Cutter Biological

Berkeley, CA 94710 USA
Division of Miles Laboratories, Inc.
Elkhart, IN 46514 USA
Miles Laboratories, Ltd., Canada

EDITORIAL INDEX

ELECTROCAUTERY

Meeting the challenge of cervical cone biopsy. 96, Dec, oa

ELECTRODES

Coping with complications from fetal scalp electrodes. 28, Nov, oa

ELECTRODESICATION

Evaluating male partners of condyloma patients. 194, Oct, oa

EMBOLISM, AIR

Contraindications to the gravity suit. 15, Sep, et

EMERGENCIES

Cardiac arrhythmias in pregnant women. 158, Jul, oa

Coping successfully with cord prolapse. 198, Jul, oa

CPR saving high-risk newborns in San Diego. 220, Aug, nl

Expanding the role of β -sympathomimetic drugs in obstetric emergencies. 122, Jul, oa

For controlling intractable hemorrhage: the gravity suit. 22, Jul, oa

Foreword: Preparing for the inevitable. 6, Jul, ed

How to avoid or minimize urologic injuries in surgery. 213, Jul, oa

Nonobstetric abdominal pain in pregnancy: What's the cause? 64, Jul, oa

Pediatric gyn trauma. 147, Jul, oa

Recognizing and treating toxic shock. 43, Jul, oa

What to do when a surgical wound separates. 35, Jul, oa

When you suspect ectopic pregnancy. 91, Jul, oa

ENDOMETRIAL HYPERPLASIA

Detecting endometrial cancer and precursor lesions. 231, Sep, s

Prescribing FDA-approved drugs in nonapproved ways. 35, Aug, oa

ENDOMETRIOSIS

Update from San Francisco: the 1983 AFS report. 184, 187, 188, 189, Sep, oa

ENDOMETRIUM

Detecting endometrial cancer and precursor lesions. 231, Sep, s

How to induce ovulation. 204, 205, 206, Oct, s

Pill's many noncontraceptive benefits. 148, 150, Oct, oa

Scanning the pelvis for neoplasia. 120, Dec, oa

ENDORPHINS

PMS—looking for new answers to an old problem. 117, Aug, oa

ENDOSCOPY (see LAPAROSCOPY)

ENEMAS

Preps and enemas—keep or discard? 244, 247, 248, Nov, oa

ENTEROTOXINS

Recognizing and treating toxic shock. 44, Jul, oa

EPIDEMIOLOGY

Tricks of the trade in displaying data. 87, Sep, oa

What matching achieves. 171, Nov, oa

EPINEPHRINE

Little-known ob-gyn milestone—Mendelson on gastric aspiration. 101, Oct, oa

EPISIOTOMY

Is the mediolateral episiotomy outdated? 15, Aug, et

Is the mediolateral episiotomy outdated? Author's reply. 15, Aug, et

EPITHELIUM

Cervical condyloma and CIN: How are they related? 116, 118, 121, 122, Sep, oa

Colposcopic patterns of papillomavirus infection. 109, 110, 112, Sep, oa

Ovarian Ca—more on cytoreduction. 68, Nov, oa

Technique for following irradiated patients. 103, 104, 106, 109, 111, Nov, oa

EPSTEIN-BARR VIRUS

Dealing with viral hepatitis during pregnancy. 29, 33, Sep, oa

Herpesviruses: why control is difficult. 61, 62, 63, 72, Aug, oa

EQUIPMENT AND SUPPLIES

Better way to screen for osteoporosis. 116, Nov, oa

Chemiluminescence as a biologic marker. 47, T84, oa

Chorionic villi sampling: its promise and its problems. A source of fetal cells. 31, T84, oa

Chorionic villi sampling: its promise and its problems. Potential for improving fetal treatment. 38, T84, oa

Current role of CO₂ lasers in ob-gyn surgery. 107, T84, oa

For controlling intractable hemorrhage: the gravity suit. 22, Jul, oa

How to choose sutures for microsurgery. 87, Nov, oa

How to select a cryosurgical unit. 101, T84, oa

New instruments and techniques for hysteroscopy. 67, T84, oa

NMR—new tool for ob-gyn imaging. 9, T84, oa

Pediatric gyn trauma. 147, Jul, oa

Update on colposcopes and their accessories. 85, T84, oa

Using the computer to estimate fetal weight. 25, T84, oa

What's available in EFM equipment. 17, T84, oa

EQUIPMENT SAFETY

Current role of CO₂ lasers in ob-gyn surgery. 117, 124, T84, oa

ERYTHROBLASTOSIS FETALIS

Managing Rh immunization. 33, Oct, pr

ESTRADIOL

Flexible prescribing of estrogens. 137, Nov, oa

ESTROGENS

Better way to screen for osteoporosis. 116, 127, 128, 131, Nov, oa

Consider the cervical factor in reproduction. 194, Aug, oa

Does prolactin affect the bone? 15, Jul, et

Does prolactin affect the bone? Author's reply. 15, Jul, et

Effects of marijuana on reproduction. 217, 218, Oct, oa

Exogenous estrogens reverse some age-related changes. 238, Oct, nl

Flexible prescribing of estrogens. 137, Nov, oa

GnRH deficiency: tailor therapy according to severity. 280, Nov, nl

Immunologic infertility: Which approaches are best? 155, Sep, oa

LDL cholesterol linked to high-pre-gestin OCs. 220, Aug, nl

Nonobstetric abdominal pain in pregnancy: What's the cause? 72, Jul, oa

PMS-looking for new answers to an old problem. 109, Aug, oa

Prescribing FDA-approved drugs in nonapproved ways. 28, Aug, oa

Techniques for following irradiated patients. 111, Nov, oa

Update from San Francisco: the 1983 AFS report. 174, Sep, oa

What can we do for Mrs. Smith? 15, Nov, ed

ESTRONE

Flexible prescribing of estrogens. 137, Nov, oa

ETHICS, MEDICAL

Chorionic villi sampling: its promise and its problems. 38, T84, oa

Ethical decisions: individual or consensus? 11, Jul, ed

How recombinant DNA technology may transform medicine and industry. 214, Aug, oa

ETHINYL ESTRADIOL

How to manage the victim of rape. 258, Sep, oa

EVISCERATION

What to do when a surgical wound separates. 35, Jul, oa

EYE DISEASES

Using vitamin E to reduce severity of RLF. 268, Sep, nl

FATTY LIVER

When liver disease complicates pregnancy. 59, 64, 65, 68, 73, Sep, ppc

FERTILIZATION, IN VITRO

How to induce ovulation. 212, 213, Oct, s

Prescribing FDA-approved drugs in nonapproved ways. 32, Aug, oa

Update from San Francisco: the 1983 AFS report. 189, 190, Sep, oa

FETAL ANEMIA

Guide to sinusoidal FHR patterns. 94, Aug, oa

FETAL ANOXIA

Coping successfully with cord prolapse. 202, Jul, oa

Fetal activity: measure of well-being. 220, Sep, oa

Guide to sinusoidal FHR patterns. 94, Aug, oa

FETAL APNEA

Fetal activity: measure of well-being. 219, 221, 224, Sep, oa

FETAL BLOOD

Safe medications during pregnancy. 45, 48, Nov, oa

FETAL DISTRESS

Closing the book on Rh disease. 9, Oct, ed

Coping successfully with cord prolapse. 201, 205, Jul, oa

Expanding the role of β -sympathomimetic drugs in obstetric emergencies. 128, 133, 136, 140, Jul, oa

Fetal activity: measure of well-being. 211, Sep, oa

Fetal distress indicating abruptio placentae. 15, Oct, efm

Loss of movement dictates evaluation. 15, Oct, efm

FETAL GROWTH

Using the computer to estimate fetal weight. 25, T84, oa

FETAL GROWTH RETARDATION

Is it time to retire "IUGR"? 15, Sep, et

Spotting and treating intrauterine growth retardation. 23, Nov, pr

When the patient has placenta previa. 18, Dec, pr

FETAL MONITORING (see also ULTRASOUND)

Coping successfully with cord prolapse. 200, Jul, oa

Coping with complications from fetal scalp electrodes. 28, Nov, oa

Ensuring optimum outcome for postdate pregnancy. 204, 205, 207, Dec, s

Expanding the role of β -sympathomimetic drugs in obstetric emergencies. 126, 128, 140, Jul, oa

Fetal activity: measure of well-being. 211, Sep, oa

Fetal distress indicating abruptio placentae. 15, Oct, efm

Guide to sinusoidal FHR patterns. 94, Aug, oa

Loss of movement dictates evaluation. 15, Oct, efm

FETAL WEIGHT

Using the computer to estimate fetal weight. 25, T84, oa

What's available in EFM equipment. 17, T84, oa

When your patient has pregnancy-induced hypertension. 42, Oct, pr

Which therapeutic agents for cardiac arrhythmias? 196, Jul, oa

FETAL MOVEMENT

Ensuring optimum outcome for postdate pregnancy. 205, 206, Dec, s

Fetal activity: measure of well-being. 211, Sep, oa

Loss of movement dictates evaluation. 15, Oct, efm

FETAL WEIGHT

Spotting and treating intrauterine growth retardation. 26, Nov, pr

FEVER

Recognizing and treating toxic shock. 43, Jul, oa

FIBRINOGEN

Managing missed abortion and antepartum fetal death. 22, 23, Sep, pr

FIBROCYSTIC BREAST DISEASE (see BREAST DISEASES)

FLUID THERAPY

Recognizing and treating toxic shock. 49, 50, Jul, oa

FMN

Chemiluminescence as a biologic marker. 52, 57, T84, oa

FOOD AND DRUG ADMINISTRATION

ACOG on AFP screening. 264, Sep, nl

Prescribing FDA-approved drugs in nonapproved ways. 27, Aug, oa

FRACTURES

Better way to screen for osteoporosis. 117, 118, 119, Nov, oa

FSH

Effects of marijuana on reproduction. 217, Oct, oa

How to induce ovulation. 199, 200, 201, Oct, s

Intricacies of spermatogenesis. 231, 232, 233, Nov, oa

New insights into follicular development. 126, 131, 132, 138, 139, Dec, oa

FUNOSEMIDE

Progress in managing hydronephrosis in utero. 48, Oct, oa

G SUITS

Contraindications to the gravity suit. 15, Sep, et

Contraindications to the gravity suit. Author's reply. 15, Sep, et

For controlling intractable hemorrhage: the gravity suit. 22, Jul, oa

Recognizing and treating toxic shock. 50, Jul, oa

GALACTORRHEA

How to induce ovulation. 201, 202, Oct, s

GALLBLADDER

Guidelines for exploring the abdomen. 166, 167, Dec, oa

GALLBLADDER DISEASES

Pill's many noncontraceptive benefits. 136, Oct, oa

GASTRIC ACID

How to treat nonobstetric abdominal pain in pregnancy. 52, Aug, oa

GENE THERAPY

How recombinant DNA technology may transform medicine and industry. 207, 208, 209, 211, Aug, oa

GENETIC MARKER

Gene linkage and prenatal diagnosis. 86, 87, Oct, oa

Genetic marker for rheumatic fever found. 221, Aug, nl

GENETIC SCREENING

Chorionic villi sampling: its promise and its problems. Potential for improving fetal treatment. 42, 43, T84, oa

Gene linkage and prenatal diagnosis. 85, Oct, oa

GENETICS

DNA probes for muscular dystrophy. 245, Dec, nl

Gene linkage and prenatal diagnosis. 85, Oct, oa

How recombinant DNA technology may transform medicine. 203, Aug, oa

Is irradiation of gonadal tissue ever safe? 15, Dec, et

GENITALIA, FEMALE

Pediatric gyn trauma. 147, Jul, oa

GENITALIA, MALE

Effects of marijuana on reproduction. 223, 224, Oct, oa

Evaluating male partners of condyloma patients. 183, Oct, oa

GERM CELL TUMORS

Ovarian germ cell tumors. 29, Oct, et

GESTATIONAL AGE

Fetal activity: measure of well-being. 211, 212, 214, Sep, oa

Using the computer to estimate fetal weight. 25, T84, oa

GLUCOCORTICOIDS

Managing acute adrenal insufficiency. 113, Jul, oa

Thyroid storm need not be lethal. 144, 146, Aug, oa

GLUCOSE

Fetal activity: measure of well-being. 215, 221, Sep, oa

New instruments and techniques for hysteroscopy. 71, 72, T84, oa

GLYCOSIDES

Cardiac arrhythmias in pregnant women. 160, Jul, oa

GONADAL DYSGENESIS

Intricacies of spermatogenesis. 225, Nov, oa

GONADOTROPINS

GnRH deficiency: tailor therapy according to severity. 280, Nov, nl

How to induce ovulation. 200, 201, 210, 212, 213, Oct, s

Intricacies of spermatogenesis. 231, 232, 233, Nov, oa

New insights into follicular development. 125, Dec, oa

Ovarian germ cell tumor. 29, Oct, et

Over-40 OC users' risk for cancer down. 239, Oct, nl

Update from San Francisco: the 1983 AFS report. 168, 189, 190, Sep, oa

When you suspect ectopic pregnancy. 91, 92, 93, 109, 111, Jul, oa

GONORRHEA

How to manage the victim of rape. 255, 257, 258, Sep, oa

PPNG infection controlled. 223, Aug, nl

GRANULOSA CELLS

New insights into follicular development. 133, Dec, oa

GRAPHS

Tricks of the trade in displaying data. 88, 91, Sep, oa

GRAVES DISEASE

Thyroid storm need not be lethal. 135, Aug, oa

GRIEF

Helping a patient surrender her child for adoption. 40, Dec, oa

EDITORIAL INDEX

GUANIDINES

How to treat nonobstetric abdominal pain in pregnancy. 52, Aug, oa

HEART CONDUCTION SYSTEM

Cardiac arrhythmias in pregnant women. 158, Jul, oa

Which therapeutic agents for cardiac arrhythmias? 187, Jul, oa

HEART DISEASE (see CARDIOVASCULAR DISEASES)

HEART FAILURE, CONGESTIVE

Cardiac arrhythmias in pregnant women. 159, Jul, oa

HEART RATE

Cardiac arrhythmias in pregnant women. 160, 163, Jul, oa

HEART RATE, SINUSOIDAL

Guide to sinusoidal FHR patterns. 94, Aug, oa

HEMODIALYSIS

Recognizing and treating toxic shock. 53, 55, Jul, oa

HEMORRHAGE

For controlling intractable hemorrhage: the gravity suit. 22, Jul, oa

Prescribing FDA-approved drugs in nonapproved ways. 42, Aug, oa

HEMOSTASIS

For controlling intractable hemorrhage: the gravity suit. 24, Jul, oa

Meeting the challenge of cervical cone biopsy. 96, Dec, oa

HEMOSTATIC TECHNIQUES

For controlling intractable hemorrhage: the gravity suit. 24, Jul, oa

HEPATITIS, VIRUSES

Dealing with viral hepatitis during pregnancy. 29, Sep, oa

HBIG prophylaxis for offspring of HBsAg-carrier mothers. 268, Sep, nl

When liver disease complicates pregnancy. 64, Sep, ppc

HERPES GESTATIONIS

Your pregnant patient's rash: Is it PUPP syndrome? 153, Dec, oa

HERPES SIMPLEX

Coping with complications from fetal scalp electrodes. 30, 33, Nov, oa

HERPESVIRUS INFECTIONS

Dealing with viral hepatitis during pregnancy. 29, 33, Sep, oa

Herpesviruses: why control is difficult. 61, Aug, oa

HIRSUTISM

Prescribing FDA-approved drugs in nonapproved ways. 32, Aug, oa

HISTOCOMPATIBILITY

Update from San Francisco: the 1983 AFS report. 168, 169, Sep, oa

HISTOGRAM

Tricks in displaying data. 94, Sep, oa

HISTOLOGY

Cervical condyloma and CIN: How are they related? 129, 132, Sep, oa

Tracking an elusive entity—microinvasive cervical cancer. 154, 159, Aug, s

HISTORY TAKING (see

MEDICAL HISTORY TAKING)

HORMONES

Prescribing FDA-approved drugs in nonapproved ways. 28, 32, 35, Aug, oa

HOSPITAL DEPARTMENTS

New for high-risk ob—the maternal-fetal ICU. 171, Aug, oa

HYBRID CELLS

Gene linkage and prenatal diagnosis. 87, Oct, oa

HYBRIDIZATION

Gene linkage and prenatal diagnosis. 87, 88, Oct, oa

HYDRAZINE

Guide to MgSO₄ therapy for PIH. 66, Dec, cd

When your patient has pregnancy-induced hypertension. 39, Oct, pr

HYDRAZINICS

Managing polyhydramnios. 17, Aug, pr

HYDROCEPHALUS

AMA group weighs benefits of fetal surgery. 247, Dec, nl

HYDROCHLORIC ACID

Little-known ob-gyn milestone—Mendelson on gastric aspiration. 101, Oct, oa

Nonobstetric abdominal pain in pregnancy:

What's the cause? 80, Jul, oa

HYDROCORTISONE

Managing acute adrenal insufficiency. 114, 115, 120, Jul, oa

When your patient has pregnancy-induced hypertension. 39, Oct, pr

HYDRONEPHROSIS

AMA group weighs benefits of fetal surgery. 247, Dec, nl

Problems in diagnosing hydronephrosis in utero. 80, Oct, oa

Progress in managing hydronephrosis in utero. 47, Oct, oa

HYPERBILIRUBINEMIA

Loss of movement dictates evaluation. 24, Oct, em

HYPERGLYCEMIA

Minimizing side effects from β -adrenergic tocolytics. 175, Oct, oa

HYPERINSULINEMIA

Minimizing side effects from β -adrenergic tocolytics. 170, Oct, oa

HYPERPLASIA

Cervical condyloma and CIN: How are they related? 116, Sep, oa

HYPERREFLEXIA

When your patient has pregnancy-induced hypertension. 39, Oct, pr

HYPERTENSION

Pills' many noncontraceptive benefits. 136, Oct, oa

HYPERTENSION, PREGNANCY-INDUCED

Guide to MgSO₄ therapy for PIH. 65, Dec, cd

When your patient has pregnancy-induced hypertension. 36, Oct, pr

HYPERTHYROIDISM

Thyroid storm need not be lethal. 135, Aug, oa

HYPERTONIC UTERINE ACTIVITY

Expanding the role of β -sympathomimetic

drugs in obstetric emergencies. 126, Jul, oa

HYPOGLYCEMIA

PMS—looking for new answers to an old problem. 103, 104, Aug, oa

HYPOKALEMIA

Minimizing side effects from β -adrenergic tocolytics. 170, Oct, oa

HYPOMASTIA

What you should know about reconstructive breast surgery. 177, 178, Nov, oa

HYPOTENSION

For controlling intractable hemorrhage: the gravity suit. 25, Jul, oa

Minimizing side effects from β -adrenergic tocolytics. 175, Oct, oa

Recognizing and treating toxic shock. 43, Jul, oa

HYPOTENSION, FETAL

Coping successfully with cord prolapse. 200, Jul, oa

HYPOTHALAMUS

GnRH deficiency: tailor therapy according to severity. 280, Nov, nl

Update from San Francisco: the 1983 AFS report. 168, Sep, oa

HYPOTHYROIDISM

How to induce ovulation. 201, 202, Oct, s

HISTERECTOMY

Detecting endometrial cancer and precursor lesions. 233, 234, 239, 240, 244, Sep, s

Examining patients who have had conization or hysterectomy. 108, 111, Dec, oa

How to treat nonobstetric abdominal pain in pregnancy. 47, Aug, oa

Hysterectomy costs cut by prophylaxis. 237, Oct, nl

Ovarian Ca—more on cytoreduction. 68, 70, Nov, oa

Small-cell cancer of the cervix. 119, 131, Oct, ppc

Tracking an elusive entity—microinvasive cervical cancer. 168, Aug, s

HYSTEROSCOPY

New instruments and techniques for hysteroscopy. 67, T84, oa

Update from San Francisco: the 1983 AFS report. 169, 170, 174, Sep, oa

IMMUNE SYSTEM

Immunologic infertility: Which approaches are best? 141, Sep, oa

IMMUNIZATION

CDC urges vaccinating adults as rubella in children disappears. 246, Dec, nl

Closing the book on Rh disease. 10, Oct, ed

Dealing with viral hepatitis during pregnancy. 39, 43, 47, Sep, oa

HBIG PROPHYLAXIS

HBIG prophylaxis for offspring of HBsAg-carrier mothers. 268, Sep, nl

Managing Rh immunization. 33, Oct, pr

Update from San Francisco: the 1983 AFS report. 167, Sep, oa

IMMUNIZATION, PASSIVE

Dealing with viral hepatitis during pregnancy. 39, 43, 47, Sep, oa

Immunologic infertility: Which approaches are best? 141, Sep, oa

INFECTIVITY

Cervical factor in reproduction. 187, Aug, oa

Current role of CO₂ lasers in ob-gyn surgery. 116, T84, oa

Effects of marijuana on reproduction. 224, Oct, oa

Fertility problems of DES daughters. 197, Aug, oa

How to induce ovulation. 199, Oct, s

Immunologic infertility: Which approaches are best? 141, Sep, oa

Problems linked to uterine myomas. 265, 266, 267, 268, 269, Nov, s

Update from San Francisco: the 1983 AFS report. 167, Sep, oa

INFORMATION DISSEMINATION

Tricks of the trade in displaying data. 87, Sep, oa

INFORMED CONSENT
Progress in managing hydronephrosis in utero. 75, Oct, oa

INFUSIONS, INTRA-ARTERIAL
Recognizing and treating toxic shock. 49, 50, 53, Jul, oa

INFUSIONS, PARENTERAL
Guide to $MgSO_4$ therapy for PIH. 65, Dec, cd

INSEMINATION, ARTIFICIAL
Consider the cervical factor in reproduction. 190, 194, 195, 196, Aug, oa

INSULIN
How recombinant DNA technology may transform medicine. 211, 212, Aug, oa

New diet advice for diabetics? Author's reply. 15, Aug, et

INSURANCE, HEALTH, REIMBURSEMENT
What you should know about reconstructive breast surgery. 179, 193, 196, Nov, oa

INTENSIVE CARE UNITS
New for high-risk ob—the maternal-fetal ICU. 171, Aug, oa

INTENSIVE CARE UNITS, NEONATAL
How NICU babies fare after discharge. 240, Oct, nl

Neonatal death: caring for the parents. 24, Sep, pr

INTESTINE, SMALL
Guidelines for exploring the abdomen. 163, Dec, oa

INTRAOPERATIVE COMPLICATIONS
How to avoid or minimize urologic injuries in surgery. 213, Jul, oa

INTRAUTERINE DEVICES
How to insert an IUD. 163, Sep, cd

Paracervical block for IUD insertion. 17, Nov, et

Paracervical block for IUD insertion. Author's reply. 17, Nov, et

Problems linked to uterine myomas. 276, 277, Nov, s

INTUBATION
Choosing anesthesia for high-risk ob patients. 75, 82, 84, Sep, oa

IN VITRO FERTILIZATION (see FERTILIZATION, IN VITRO)

IODIDES
Thyroid storm need not be lethal. 141, Aug, oa

IONIZATION
Obstetric use of local anesthetics. 48, 51, Dec, oa

IRON DEFICIENCY
Prescribing FDA-approved drugs in nonapproved ways. 40, 41, Aug, oa

IRON DEXTRAN COMPLEX
Prescribing FDA-approved drugs in nonapproved ways. 40, 41, Aug, oa

ISCHEMIA
Minimizing side effects from β -adrenergic tocolytics. 170, 171, Oct, oa

JAUNDICE
Dealing with viral hepatitis during pregnancy. 29, 30, 36, Sep, oa

When liver disease complicates pregnancy. 59, 60, 65, 73, ppc

KALLIKREIN
Consider the cervical factor in reproduction. 196, Aug, oa

KIDNEY DISEASES
Problems in diagnosing hydronephrosis in utero. 80, Oct, oa

Progress in managing hydronephrosis in utero. 47, Oct, oa

KIDNEY FAILURE
When liver disease complicates pregnancy. 65, 68, 73, ppc

KIDNEY OBSTRUCTION
Progress in managing hydronephrosis in utero. 64, 71, 72, Oct, oa

LABOR (see also DELIVERY)
Ensuring optimum outcome for postdate pregnancy. 206, 207, Dec, s

Fetal activity: measure of well-being. 215, 218, Sep, oa

How worthwhile are membrane stripping and amniotomy? 173, Dec, oa

Preps and enemas—keep or discard? 241, Nov, oa

LABOR, INDUCED
Coping successfully with cord prolapse. 205, Jul, oa

How worthwhile are membrane stripping and amniotomy? 173, Dec, oa

Managing missed abortion and antepartum fetal death. 17, Sep, pr

LABOR, PREMATURE
Choosing anesthesia for high-risk ob patients. 80, Sep, oa

Coping successfully with cord prolapse. 199, Jul, oa

Expanding the role of β -sympathomimetic drugs in obstetric emergencies. 125, 126, Jul, oa

Fetal distress indicating abruptio placentae. 15, Oct, em

Minimizing side effects from β -adrenergic tocolytics. 169, Oct, oa

Prescribing FDA-approved drugs in nonapproved ways. 42, Aug, oa

LABOR PRESENTATION
Choosing anesthesia for high-risk ob patients. 82, Sep, oa

Coping successfully with cord prolapse. 199, Jul, oa

Expanding the role of β -sympathomimetic drugs in obstetric emergencies. 136, 139, Jul, oa

Strategy for managing breech presentation. 16, 18, Jul, et

Strategy for managing breech presentation. Author's reply. 18, Jul, et

LABORATORY TESTING (see DIAGNOSTIC TESTS)

LACTATE DEHYDROGENASE
Ovarian germ cell tumors. 29, Oct, et

Ovarian germ cell tumors. Author's reply. 29, Oct, et

LACTATION
Effects of marijuana on reproduction. 223, Oct, oa

LAPAROSCOPY
When you suspect ectopic pregnancy. 98, 100, Jul, oa

LAPAROTOMY
Guidelines for exploring the abdomen. 161, Dec, oa

LASERS
Cervical condyloma and CIN: How are they related? 134, Sep, oa

Current role of CO_2 lasers in ob-gyn surgery. 107, T84, oa

Evaluating male partners of condyloma patients. 194, Oct, oa

Update from San Francisco: the 1983 AFS report. 169, Sep, oa

LEGISLATION
Helping a patient surrender her child for adoption. 30, Dec, oa

Work and pregnancy: guidelines needed. 9, Aug, ed

LEYDIG CELLS
Intricacies of spermatogenesis. 225, 226, 232, Nov, oa

LH
Effects of marijuana on reproduction. 217, Oct, oa

How to induce ovulation. 200, 201, Oct, s

Intricacies of spermatogenesis. 231, 232, 233, Nov, oa

New insights into follicular development. 131, 138, 139, Dec, oa

Prescribing FDA-approved drugs in nonapproved ways. 32, Aug, oa

LIDOCAINE
Which therapeutic agents for cardiac arrhythmias? 187, 188, Jul, oa

LINKAGE (GENETICS)
Gene linkage and prenatal diagnosis. 85, Oct, oa

LDL SOLUBILITY
Obstetric use of local anesthetics. 48, Dec, oa

LIPOPROTEINS
Flexible prescribing of estrogens. 151, 155, Nov, oa

LDL cholesterol linked to high-progestin OCs. 220, Aug, ni

New insights into follicular development. 131, 133, 141, Dec, oa

LIVER
Guidelines for exploring the abdomen. 166, Dec, oa

LIVER DISEASES
Dealing with viral hepatitis during pregnancy. 29, Sep, oa

When liver disease complicates pregnancy. 59, Sep, ppc

LIVER FUNCTION TESTS
When liver disease complicates pregnancy. 60, 73, Sep, ppc

LIVER METABOLISM
Flexible prescribing of estrogens. 137, 140, 151, Nov, oa

LUCIFERASE
Chemiluminescence as a biologic marker. 57, 60, T84, oa

LUCIFERIN
Chemiluminescence as a biologic marker. 57, 60, T84, oa

LYMPH NODES
Lymph node x-rays as possible prognostic

indicators. 237, Oct, ni

What treatment alternatives for minimal breast cancer? 109, Oct, oa

MAGNESIUM SULFATE
Choosing anesthesia for high-risk ob patients. 84, Sep, oa

Dos and don'ts of treating preeclampsia with $MgSO_4$. 163, Oct, oa

Guide to $MgSO_4$ therapy for PIH. 65, Dec, cd

When your patient has pregnancy-induced hypertension. 39, Oct, pr

MAMMOGRAPHY
Breast disease—first line of defense. 11, Sep, ed

Lumps: When is close follow-up appropriate? 205, 209, Sep, oa

What treatment alternatives for minimal breast cancer? 107, 108, Oct, oa

MALPRACTICE
Malpractice update. 11, Dec, ed

MAPS
Tricks of the trade in displaying data. 100, Sep, oa

MARIJUANA
Effects of marijuana on reproduction. 217, Oct, oa

MASTECTOMY
Radiation lesion may resemble recurrent Ca. 281, Nov, ni

Radiotherapy's benefit for breast cancer dubious. 266, Sep, ni

What treatment alternatives for minimal breast cancer? 108, Oct, oa

What you should know about reconstructive breast surgery. 186, 191, Nov, oa

MASTOPEXY
What you should know about reconstructive breast surgery. 185, 186, Nov, oa

MATCHING
What matching achieves. 171, Nov, oa

MATERNAL-FETAL EXCHANGE
Choosing anesthesia for high-risk ob patients. 80, 82, 84, Sep, oa

Dealing with viral hepatitis during pregnancy. 35, 36, 39, Sep, oa

Effects of marijuana on reproduction. 218, Oct, oa

Minimizing side effects from β -adrenergic tocolytics. 176, 179, Oct, oa

Obstetric use of local anesthetics. 52, 54, 56, 57, Dec, oa

Safe medications during pregnancy. 40, 41, Nov, oa

Which therapeutic agents for cardiac arrhythmias? 187, Jul, oa

MECONIUM
Effects of marijuana on reproduction. 222, Oct, oa

Ensuring optimum outcome for postdate pregnancy. 204, 207, 210, Dec, s

MEDICAL HISTORY TAKING
How to manage the victim of rape. 254, 255, 257, Sep, oa

Lumps: When is close follow-up appropriate? 204, 205, 206, 209, Sep, oa

PMS—looking for new answers to an old problem. 126, Aug, oa



(butorphanol tartrate)

the effective analgesic with the safety difference

Brief Summary of Prescribing Information

STADOL® (butorphanol tartrate)

For complete information, consult Official Package Circular.

(2) 12/10/79

INDICATIONS AND USAGE—Stadol is recommended for the relief of moderate to severe pain. Stadol can be used for preoperative or preanesthetic medication, as a supplement to balanced anesthesia, and for the relief of prepartum pain.

CONTRAINDICATIONS—Stadol should not be administered to patients who have been shown to be hypersensitive to it.

WARNINGS—Patients Physically Dependent on Narcotics: Because of its antagonist properties, Stadol is not recommended for patients physically dependent on narcotics. Detoxification in such patients is required prior to use.

Due to the difficulty in assessing addiction in patients who have recently received substantial amounts of narcotic medication, caution should be used in the administration of Stadol. Detoxification of such patients prior to usage should be carefully considered.

Drug Dependence: Special care should be exercised in administering Stadol to emotionally unstable patients, and to those with a history of drug abuse. When long-term therapy is contemplated, such patients should be closely supervised. Even though Stadol has a low potential for drug abuse liability, care should be taken that individuals who may be prone to drug abuse are closely supervised. It is important to avoid increases in dose and frequency of injections by the patient and to prevent the use of the drug in anticipation of pain rather than for the relief of pain.

Head Injury and Increased Intramural Pressure: Although there is no clinical experience in patients with head injury, it can be assumed that Stadol, like other potent analgesics, elevates cerebrospinal fluid pressure. Therefore the use of Stadol in cases of head injury can produce effects (e.g., miosis) which may obscure the clinical course of patients with head injuries. In such patients Stadol must be used with extreme caution and only if its use is deemed essential.

Cardiovascular Effects: Because Stadol increases the work of the heart, especially the pulmonary circuit, the use of this drug in acute myocardial infarction or in cardiac patients with ventricular dysfunction or coronary insufficiency should be limited to those who are hypersensitive to morphine sulfate or meperidine.

PRECAUTIONS—Certain Respiratory Conditions: Because Stadol causes some respiratory depression, it should be administered only with caution and low dosage to patients with respiratory depression (e.g., from other medication, uremia, or severe infection), severely limited respiratory reserve, bronchial asthma, obstructive respiratory conditions, or cyanosis.

Impaired Renal or Hepatic Function: Although laboratory tests have not indicated that Stadol causes or increases renal or hepatic impairment, the drug should be administered with caution to patients with such impairment. Extensive liver disease may predispose to greater side effects and greater activity from the usual clinical dose, possibly the result of decreased metabolism of the drug by the liver.

Biliary Surgery: Clinical studies have not been done to establish the safety of Stadol administration to patients about to undergo surgery of the biliary tract.

Usage as a Preoperative or Preanesthetic Medication: Slight increases in systolic blood pressure may occur, therefore caution should be employed when Stadol is used in the hypertensive patient.

Usage in Balanced Anesthesia: The use of pancuronium in combination with Stadol may cause an increase in conjunctival changes.

Usage in Pregnancy: The safety of Stadol for use in pregnancy prior to the labor period has not been established; therefore, this drug should be used in pregnant patients only when the judgment of the physician uses is deemed essential to the welfare of the patient.

Reproduction studies have been performed in rats, mice and rabbits and have revealed no evidence of impaired fertility or harm to the fetus due to Stadol at about 2.5 to 5 times the human dose.

Usage in Labor and Delivery: Safety to the mother and fetus following administration of Stadol during labor has been established. Patients receiving Stadol during labor have experienced no adverse effects other than those observed with commonly used analgesics. Stadol should be used with caution in women delivering premature infants.

Usage in Nursing Mothers: The use of Stadol in lactating mothers who are nursing their infants is not recommended since it is not known whether this drug is excreted in human milk. Stadol has been used safely for labor pain in mothers who subsequently nursed their infants.

Usage in Children: Safety and efficacy in children below age 18 years have not been established.

ADVERSE REACTIONS—The most frequent adverse reactions in 1250 patients treated with Stadol are: sedation (503, 40%), nausea (62, 6%), clammy/sweating (76, 6%). Less frequent reactions are: headache (55, 3%), vertigo (33, 3%), floating feeling (33, 3%), dizziness (23, 2%), lethargy (19, 2%), confusion (15, 1%), lightheadedness (12, 1%). Other adverse reactions which may occur (reported incidence of less than 1%):

CNS: nervousness, unusual dreams, agitation, euphoria, hallucinations

Autonomic: flushing and warmth, dry mouth, sensitivity to cold

Cardiovascular: palpitation, increase or decrease of blood pressure

Gastrointestinal: vomiting

Respiratory: slowing of respiration, shallow breathing

Dermatological: rash or hives

Eye: diplopia or blurred vision

OVERDOSAGE—Manifestations: Although there have been no experiences of overdose with Stadol during clinical trials, this may occur due to accidental or intentional misuse as well as therapeutic use. Based on the pharmacology of Stadol, overdose could produce some degree of respiratory depression and variable cardiovascular and central nervous system effects.

Treatment: The immediate treatment of suspected Stadol overdose is intravenous naloxone. The respiratory and cardiac status of the patient should be evaluated constantly and appropriate supportive measures instituted, such as oxygen, intravenous fluids, vasopressors and assisted or controlled respiration.

HOW SUPPLIED—Stadol (butorphanol tartrate) injection for I.M. or I.V. use, is available as follows:

NDC 0015-5644-20—2 mg per ml, 2-ml vial

NDC 0015-5645-20—1 mg per ml, 1-ml vial

NDC 0015-5646-20—2 mg per ml, 1-ml vial

NDC 0015-5646-23—2 mg per ml, 1-ml Disposable Syringe

NDC 0015-5648-20—2 mg per ml, 10-ml multi-dose vial

EDITORIAL INDEX

When you suspect ectopic pregnancy. 91, 100, 106, 109, Jul, oa

MEDICAL PROCEDURES (see

TECHNOLOGY, MEDICAL)

MEDICAL TERMINOLOGY

Detecting endometrial cancer and precursor lesions. 231, Sep, s

Is it time to retire 'IUGR'? 15, Sep, et

MEDROXYPROGESTERONE

Prescribing FDA-approved drugs in nonapproved ways. 35, 36, Aug, oa

MEIOSIS

Gene linkage and prenatal diagnosis. 85, Oct, oa

MEMBRANE STRIPPING

How worthwhile are membrane stripping and amniotomy? 174, 175, Dec, oa

MEMBRANES, PREMATURE RUPTURE

Coping successfully with cord prolapse. 199, Jul, oa

MEMBRANES, RUPTURE

How worthwhile are membrane stripping and amniotomy? 173, Dec, oa

MENOPAUSE

Better way to screen for osteoporosis. 116, Nov, oa

Exogenous estrogens reverse some age-related changes. 238, Oct, nl

Flexible prescribing of estrogens. 137, Nov, oa

Prescribing FDA-approved drugs in nonapproved ways. 32, Aug, oa

What can we do for Mrs. Smith? 11, Nov, ed

MENOTROPINS

Prescribing FDA-approved drugs in nonapproved ways. 32, Aug, oa

MENSTRUATION

Diagnostic clues from vaginal odors. 212, 213, Nov, oa

Lumps: When is close follow-up appropriate? 204, 205, 206, 209, Sep, oa

New insights into follicular development. 125, Dec, oa

Pills: What are nonoral contraceptive benefits. 136, 137, Oct, oa

PMS—looking for new answers to an old problem. 102, Aug, oa

Recognizing and treating toxic shock. 44, 45, 55, 59, Jul, oa

Update from San Francisco: the 1983 AFS report. 167, 168, Sep, oa

MENSTRUATION DISORDERS

Fertility problems of DES daughters. 198, Aug, oa

Problems linked to uterine myomas. 268, 269, 270, 271, 272, Nov, s

METHIMAZOLE

Thyroid storm need not be lethal. 141, Aug, oa

METRONIDAZOLE

Prescribing FDA-approved drugs in nonapproved ways. 36, Aug, oa

MICROBIOLOGY, INDUSTRIAL

How recombinant DNA technology may transform medicine and industry. 211, 212, 213, Aug, oa

MICROSCOPY, ELECTRON

Cervical condyloma and CIN: How are they

related? 121, Sep, oa

Small-cell cancer of the cervix. 119, 120, 121, Oct, ppc

MICROSURGERY (see SURGERY)

MILK

Diet for preterm infants. 237, Oct, nl

MOLECULAR BIOLOGY

How recombinant DNA technology may transform medicine and industry. 103, Aug, oa

MONOAMINE OXIDASE

PMS—looking for new answers to an old problem. 112, Aug, oa

MORBIDITY AND MORTALITY

Better way to screen for osteoporosis. 117, 118, 119, Nov, oa

Breast disease—first line of defense. 11, Sep, ed

Colposcopic patterns of papillomavirus infection. 107, Sep, oa

Coping successfully with cord prolapse. 205, 208, 209, Jul, oa

Dealing with viral hepatitis during pregnancy. 29, Sep, oa

Detecting endometrial cancer and precursor lesions. 247, Sep, s

Dos and don'ts of treating preeclampsia with MgSO₄. 163, Oct, oa

How NICU babies fare after discharge. 240, Oct, nl

Hysterectomy costs cut by prophylaxis. 237, Oct, nl

Managing missed abortion and antepartum fetal death. 17, Sep, pr

Neonatal death: caring for the parents. 24, Sep, pr

Nonobstetric abdominal pain in pregnancy: What's the cause? 76, Jul, oa

Recognizing and treating toxic shock. 55, 59, Jul, oa

Strategy for managing breech presentation. Author's reply. 20, Jul, et

Thyroid storm need not be lethal. 146, Aug, oa

Tracking tubal sterilization deaths. 222, Aug, nl

When you suspect ectopic pregnancy. 91, Jul, oa

When your patient has pregnancy-induced hypertension. 36, Oct, pr

Why are cervical Ca rates rising in younger women? 245, Dec, nl

MUSCULAR DYSTROPHY

DNA probes for muscular dystrophy. 245, Dec, nl

MUTAGENS

Safe medications during pregnancy. 53, Nov, oa

MUTATION

How recombinant DNA technology may transform medicine and industry. 207, Aug, oa

MYOCARDIAL DISEASES

Minimizing side effects from β -adrenergic tachycardics. 170, 171, Oct, oa

MYOMAS

Problems linked to uterine myomas. 265, Nov, s

BRISTOL™

Bristol Laboratories
Division of Bristol-Myers Company
Syracuse, New York 13201

NADP Chemiluminescence as a biologic marker. 52, 57, 60, T84, oa

HALOXONE Recognizing and treating toxic shock. 53, Jul, oa

NECROSIS Radiation lesion may resemble recurrent. Ca 281, Nov, n1

NEEDLES How to choose sutures for microsurgery. 87, Nov, oa

NEONATE (see INFANT, NEWBORN)

NEONATOLOGY (see PERINATOLOGY)

NEOPLASM INVASIVENESS Cervical condyloma and CIN: How are they related? 116, Sep, oa

Colposcopic patterns of papillomavirus infection. 107, 109, Sep, oa

Detecting endometrial cancer and precursor lesions. 231, Sep, s

Tracking an elusive entity—microinvasive cervical cancer. 151, Aug, s

What treatment alternatives for minimal breast cancer? 107, 108, Oct, oa

NEOPLASM METASTASIS Detecting endometrial cancer and precursor lesions. 244, 245, Sep, s

Ovarian Ca—more on cytoreduction. 68, Nov, oa

Thyroid storm need not be lethal. 141, Aug, oa

NEOPLASM STAGING Scanning the pelvis for neoplasia. 117, 120, Dec, oa

What treatment alternatives for minimal breast cancer? 107, Oct, oa

NEOPLASMS NMR—new tool for ob-gyn imaging. 13, 15, T84, oa

NEOVASCULARIZATION What treatment alternatives for minimal breast cancer? 108, Oct, oa

NERVE FIBERS Obstetric use of local anesthetics. 46, 47, Dec, oa

NEURAL TUBE DEFECTS ACOG on AFP screening. 264, Sep, n1

New assay for confirming fetal NTDs. 247, Dec, n1

NITROUS OXIDE How to select a cryosurgical unit. 101, T84, oa

NONSTRESS TEST Protocol for the nipple-stimulation CST. 157, Oct, oa

NUCLEAR MAGNETIC RESONANCE Breast disease—first line of defense. 12, Sep, ed

NMR—new tool for ob-gyn imaging. 9, T84, oa

NURSING STAFF New for high-risk ob—the maternal-fetal ICU. 172, 174, Aug, oa

OBSTETRICS/GYNECOLOGY, SPECIALTY Breast disease—first line of defense. 11, Sep, ed

Computer applications in the ob-gyn office. 71, Dec, oa

Contraindications to the gravity suit. 15, Sep, et

Current role of CO₂ lasers in ob-gyn surgery. 107, T84, oa

Ethical decisions: individual or consensus? 11, Jul, ed

Foreword: Preparing for the inevitable. 6, Jul, ed

Malpractice update. 11, Dec, ed

Pediatric gyn trauma. 147, Jul, oa

Prescribing FDA-approved drugs in nonapproved ways. 27, Aug, oa

Strategy for managing breech presentation. 18, Jul, et

ODORS Diagnostic clues from vaginal odors. 199, Nov, oa

OLIGOHYDRAMNOS Ensuring optimum outcome for postdate pregnancy. 204, 205, Dec, s

Problems in diagnosing hydronephrosis in utero. 81, 82, Oct, oa

Progress in managing hydronephrosis in utero. 54, 57, 64, 66, Oct, oa

OLIGOSPERMIA Consider the cervical factor in reproduction. 196, Aug, oa

OPHTHALMOLOGY Using vitamin E to reduce severity of RLF. 268, Sep, n1

ORGANIC MENTAL DISORDERS When to refer psychiatric problems. 252, Nov, oa

OSTEOPOROSIS Better way to screen for osteoporosis. 116, Nov, oa

Does prolactin affect the bone? 15, Jul, et

Does prolactin affect the bone? Author's reply. 15, Jul, et

Nonhormonal approach to osteoporosis debated. 280, Nov, n1

Prescribing FDA-approved drugs in nonapproved ways. 28, Aug, oa

What can we do for Mrs. Smith? 11, Nov, ed

OVARIAN CYSTS Prescribing FDA-approved drugs in nonapproved ways. 36, Aug, oa

OVARIAN DISEASES Pill's many noncontraceptive benefits. 148, 150, Oct, oa

OVARIAN NEOPLASMS Ovarian Ca—more on cytoreduction. 68, Nov, oa

Ovarian germ cell tumors. 29, Oct, et

Ovarian germ cell tumors. Author's reply. 29, Oct, et

Over-40 OC users' risk for cancer down. 239, Oct, n1

Scanning the pelvis for neoplasia. 115, Dec, oa

OVULATION Consider the cervical factor in reproduction. 195, Aug, oa

Effects of marijuana on reproduction. 218, 219, 222, Oct, oa

GnRH deficiency: tailor therapy according to severity. 280, Nov, n1

New insights into follicular development. 133, 134, Dec, oa

Update from San Francisco: the 1983 AFS report. 167, 168, 189, Sep, oa

OVULATION INDUCTION How to induce ovulation. 199, Oct, s

Prescribing FDA-approved drugs in nonapproved ways. 28, 32, Aug, oa

Update from San Francisco: the 1983 AFS report. 189, Sep, oa

OVUM New insights into follicular development. 132, 133, Dec, oa

OXYGEN Little-known ob-gyn milestone—Mendelson on gastric aspiration. 101, Oct, oa

OXYTOCIN Expanding the role of β -sympathomimetic drugs in obstetric emergencies. 126, Jul, oa

Managing missed abortion and antepartum fetal death. 17, 20, Sep, pr

Protocol for the nipple-stimulation CST. 157, Oct, oa

When your patient has pregnancy-induced hypertension. 42, Oct, pr

PAIN How to treat nonobstetric abdominal pain in pregnancy. 47, Aug, oa

Lumps: When is close follow-up appropriate? 200, Sep, oa

Nonobstetric abdominal pain in pregnancy: What's the cause? 64, Jul, oa

When you suspect ectopic pregnancy. 91, Jul, oa

PANCREATITIS How to treat nonobstetric abdominal pain in pregnancy. 48, 50, Aug, oa

Nonobstetric abdominal pain in pregnancy: What's the cause? 76, 77, Jul, oa

PAP TESTS Cervical condyloma and CIN: How are they related? 129, Sep, oa

Colposcopic patterns of papillomavirus infection. 107, 115, Sep, oa

How to insert an IUD. 163, Sep, cd

How to select a cryosurgical unit. 101, T84, oa

Tracking an elusive entity—microinvasive cervical cancer. 151, 152, Aug, s

When the pregnant patient has an abnormal Pap smear. 77, Aug, oa

PAPILLOMAVIRUSES (see also CERVIX NEOPLASMS) Cervical condyloma and CIN: How are they related? 116, Sep, oa

Colposcopic patterns of papillomavirus infection. 107, Sep, oa

Evaluating male partners of condyloma patients. 183, Oct, oa

HPV and cervical cancer. 239, Oct, n1

PARASYMPATHOLYTICS How to treat nonobstetric abdominal pain in pregnancy. 52, Aug, oa

PARASYMPATHOMIMETICS Cardiac arrhythmias in pregnant women. 160, Jul, oa

PARENTS Neonatal death: caring for the parents. 24, Sep, pr

PARTURITION Coping successfully with cord prolapse. 200, Jul, oa

Paracervical block for IUD insertion. 17, Nov, et

Paracervical block for IUD insertion. Author's reply. 17, Nov, et

PATHOLOGY Cervical condyloma and CIN: How are they related? 129, 132, Sep, oa

Detecting endometrial cancer and precursor lesions. 231, Sep, s

PATIENT EDUCATION Fitting a diaphragm. 186, Aug, oa

New for high-risk ob—the maternal-fetal ICU. 174, Aug, oa

Prepping vs. plumbing. 21, Jul, et

PELVIC INFLAMMATORY DISEASE (see ADNEXITIS)

PELVIC NEOPLASMS Scanning the pelvis for neoplasia. 115, Dec, oa

PENCILLINS How to manage the victim of rape. 257, Sep, oa

PEPSIN Nonobstetric abdominal pain in pregnancy: What's the cause? 80, Jul, oa

PEPTIC ULCER How to treat nonobstetric abdominal pain in pregnancy. 50, 52, 55, 58, Aug, oa

Nonobstetric abdominal pain in pregnancy: What's the cause? 78, 80, 84, Jul, oa

PERINATOLOGY How NICU babies fare after discharge. 240, Oct, n1

New for high-risk ob—the maternal-fetal ICU. 171, Aug, oa

PHENETHYLAMINES Expanding the role of β -sympathomimetic drugs in obstetric emergencies. 123, 124, 128, 139, 144, Jul, oa

PHENOBARBITAL When your patient has pregnancy-induced hypertension. 39, Oct, pr

PHOTON ABSORPTIOMETRY Better way to screen for osteoporosis. 116, Nov, oa

PHYSICAL EXAMINATION Breast disease—first line of defense. 12, Sep, ed

Colposcopic patterns of papillomavirus infection. 107, Sep, oa

Ensuring optimum outcome for postdate pregnancy. 188, 197, 198, Dec, s

Evaluating male partners of condyloma patients. 184, 185, 186, 187, Oct, oa

Fitting a diaphragm. 181, Aug, oa

How to insert an IUD. 163, Sep, cd

How to manage the victim of rape. 254, 255, 257, Sep, oa

Lumps: When is close follow-up appropriate? 204, 205, 206, 209, Sep, oa

Managing missed abortion and antepartum fetal death. 17, Sep, pr

EDITORIAL INDEX

Palpation adequate for annual breast exam. 264, Sep, *nl*
Pediatric gyn trauma. 147, 148, 149, Jul, *oa*
Problems in diagnosing hydronephrosis in utero. 81, 82, Oct, *oa*
Technique for following irradiated patients. 103, 104, 106, Nov, *oa*
When the patient has placenta previa. 17, Dec, *pr*
When the pregnant patient has an abnormal Pap smear. 78, 79, Aug, *oa*
When you suspect ectopic pregnancy. 91, 106, 109, Jul, *oa*
PHYSICAL STIMULATION
Protocol for the nipple-stimulation CST. 157, Oct, *oa*
PHYSICIANS, WOMEN
Update from San Francisco: the 1983 AFS report. 188, Sep, *oa*
PITUITARY HORMONE-RELEASING HORMONES
Update from San Francisco: the 1983 AFS report. 167, 168, Sep, *oa*
PITUITARY HORMONES
Effects of marijuana on reproduction. 217, Oct, *oa*
PITUITARY NEOPLASM
Prescribing FDA-approved drugs in nonapproved ways. 28, Aug, *oa*
PLACENTA
Safe medications during pregnancy. 40, 41, Nov, *oa*
Ultrasound and postdate pregnancy. 15, Jul, *et*
PLACENTA DISEASES
Managing placental abruption. 20, Dec, *pr*
When the patient has placenta previa. 17, Dec, *pr*
PLACENTAL LACTOGEN
Spotting and treating intrauterine growth retardation. 23, Nov, *pr*
PLASMAPHERESIS
Thyroid storm need not be lethal. 146, Aug, *oa*
PLASMIDS
How recombinant DNA technology may transform medicine. 203, 207, Aug, *oa*
PLATELET COUNT
Managing missed abortion and antepartum fetal death. 22, Sep, *pr*
PNEUMOCYSTIS CARINII
Herpesviruses: why control is difficult. 72, Aug, *oa*
PODOPHYLLOIN
Evaluating male partners of condyloma patients. 193, Oct, *oa*
POLYHYDRAMNOS
Problems in diagnosing hydronephrosis in utero. 82, Oct, *oa*
POLYMORPHISM (GENETICS)
Gene linkage and prenatal diagnosis. 88, Oct, *oa*
POLYPOLOIDY
Cervical condyloma and CIN: How are they related? 118, 121, Sep, *oa*
POSTCOITAL TESTS
Consider the cervical factor in reproduction. 187, Aug, *oa*
Immunologic infertility: Which approaches are best? 142, 156, Sep, *oa*
POSTMATURITY SYNDROME
Ultrasound and postdate pregnancy. 15, Jul, *et*
POSTOPERATIVE CARE
Current role of CO₂ lasers in ob-gyn surgery. 117, T84, *oa*
Ovarian Ca—more on cytoreduction. 75, 78, Nov, *oa*
POSTOPERATIVE COMPLICATIONS
Choosing the best urinary diversion for gyn patients. 260, 261, 264, Nov, *oa*
For controlling intractable hemorrhage: the gravity suit. 25, 28, Jul, *oa*
How to avoid or minimize urologic injuries in surgery. 213, Jul, *oa*
What to do when a surgical wound separates. 35, Jul, *oa*
What you should know about reconstructive breast surgery. 179, 180, 185, Nov, *oa*
POSTPARTUM DEPRESSION
When to refer psychiatric problems. 250, 252, Nov, *oa*
POTASSIUM
Minimizing side effects from β -adrenergic tocolytics. 170, Oct, *oa*
PRAC, CE MANAGEMENT
Computer applications in the ob-gyn office. 71, 72, Dec, *oa*
PRECANCEROUS CONDITIONS
Detecting endometrial cancer and precursor lesions. 231, Sep, *s*
PREECLAMPSIA (see PREGNANCY TOXEMIAS)
PREGNANCY, COMPLICATIONS
Cardiac arrhythmias in pregnant women. 158, Jul, *oa*
Closing the book on Rh disease. 9, Oct, *ed*
Coping successfully with cord prolapse. 198, Jul, *oa*
Dealing with viral hepatitis during pregnancy. 29, Sep, *oa*
Dos and don'ts of treating preeclampsia with MgSO₄. 163, Oct, *oa*
Effects of marijuana on reproduction. 222, Oct, *oa*
Ensuring optimum outcome for postdate pregnancy. 186, Dec, *s*
Ethical decisions: individual or consensus? 11, Jul, *ed*
Evaluating male partners of condyloma patients. 184, Oct, *oa*
Fertility problems of DES daughters. 198, 199, Aug, *oa*
How to treat nonobstetric abdominal pain in pregnancy. 47, Aug, *oa*
Management of amnionitis. 19, Nov, *pr*
Managing missed abortion and antepartum fetal death. 17, Sep, *pr*
Managing placental abruption. 20, Dec, *pr*
Managing polyhydramnios. 17, Aug, *pr*
New for high-risk ob—the maternal-fetal ICU. 171, Aug, *oa*
Nonobstetric abdominal pain in pregnancy: What's the cause? 64, Jul, *oa*
Problems linked to uterine myomas. 272, 273, Nov, *s*
Spotting and treating intrauterine growth retardation. 23, Nov, *pr*
Ultrasound and postdate pregnancy. 15, Jul, *et*
When liver disease complicates pregnancy. 59, Sep, *ppc*
When the patient has placenta previa. 17, Dec, *pr*
When your patient has pregnancy-induced hypertension. 36, Oct, *pr*
When you suspect ectopic pregnancy. 91, Jul, *oa*
Which therapeutic agents for cardiac arrhythmias? 189, 195, Jul, *oa*
PREGNANCY IN DIABETES (see DIABETES, GESTATIONAL)
PREGNANCY, PROLONGED
Ensuring optimum outcome for postdate pregnancy. 186, Dec, *s*
Ultrasound and postdate pregnancy. 15, Jul, *et*
PREGNANCY TESTS
When you suspect ectopic pregnancy. 91, 92, 93, 109, 111, Jul, *oa*
PREGNANCY TOXEMIAS
Choosing anesthesia for high-risk ob patients. 84, Sep, *oa*
Dos and don'ts of treating preeclampsia and eclampsia with MgSO₄. 163, Oct, *oa*
Guide to MgSO₄ therapy for PIH. 66, Dec, *ed*
PMS—looking for new answers to an old problem. 122, Aug, *oa*
When liver disease complicates pregnancy. 59, Sep, *ppc*
When your patient has pregnancy-induced hypertension. 39, 42, Oct, *pr*
When liver disease complicates pregnancy. 59, Sep, *ppc*
PREMATURE LABOR (see LABOR, PREMATURE)
PREMATURE RUPTURE OF MEMBRANES (see MEMBRANES, PREMATURE RUPTURE)
PREMENSTRUAL SYNDROME
PMS—looking for new answers to an old problem. 102, Aug, *oa*
When to refer psychiatric problems. 249, 250, Nov, *oa*
PREGNATAL CARE
Chorionic villi sampling: its promise and its problems. A source of fetal cells. 31, T84, *oa*
Chorionic villi sampling: its promise and its problems. Potential for improving fetal treatment. 38, T84, *oa*
Ensuring optimum outcome for postdate pregnancy. 186, Dec, *s*
Fetal activity: measure of well-being. 211, Sep, *oa*
Gene linkage and prenatal diagnosis. 85, Oct, *oa*
Guide to sinusoidal FHR patterns. 94, Aug, *oa*
Management of amnionitis. 19, Nov, *pr*
Managing missed abortion and antepartum fetal death. 17, Sep, *pr*
Managing Rh immunization. 33, Oct, *pr*
Minimizing side effects from β -adrenergic tocolytics. 169, Oct, *oa*
NMR—new tool for ob-gyn imaging. 15, T84, *oa*
Nonobstetric abdominal pain in pregnancy: What's the cause? 64, Jul, *oa*
Problems in diagnosing hydronephrosis in utero. 80, Oct, *oa*
Progress in managing hydronephrosis in utero. 47, Oct, *oa*
When you suspect ectopic pregnancy. 91, Jul, *oa*
PREOPERATIVE CARE
How to avoid or minimize urologic injuries in surgery. 213, Jul, *oa*
Ovarian Ca—more on cytoreduction. 68, Nov, *oa*
Preps and enemas—keep or discard? 241, Nov, *oa*
PREVENTIVE MEDICINE
Closing the book on Rh disease. 9, Oct, *ed*
Hysterectomy costs cut by prophylaxis. 237, Oct, *nl*
Prepping vs. plumbing. 21, Jul, *et*
PROCAINAMIDE
Cardiac arrhythmias in pregnant women. 163, 174, Jul, *oa*
Which therapeutic agents for cardiac arrhythmias? 189, 195, Jul, *oa*
PROCAINE
Obstetric use of local anesthetics. 46, 47, 48, Dec, *oa*
PROGESTATIONAL HORMONES
LDL cholesterol linked to high-progestin OCs. 220, Aug, *nl*
PROGESTERONE
Better way to screen for osteoporosis. 128, 131, Nov, *oa*
Effects of marijuana on reproduction. 217, 218, Oct, *oa*
GnRH deficiency: tailor therapy according to severity. 280, Nov, *nl*
PMS—looking for new answers to an old problem. 109, 112, 116, Aug, *oa*

When to refer psychiatric problems. 250, Nov, oa

PROGESTOGENS
Prescribing FDA-approved drugs in nonapproved ways. 32, 35, Aug, oa

PROLACTIN
Does prolactin affect the bone? 15, Jul, et
Does prolactin affect the bone? Author's reply. 15, Jul, et
How to induce ovulation. 201, 202, Oct, s
PMS—looking for new answers to an old problem. 104, Aug, oa

PROLAPSE
Coping successfully with cord prolapse. 198, Jul, oa

Expanding the role of β -sympathomimetic drugs in obstetric emergencies. 140, Jul, oa

PROPANOLAMINES
Expanding the role of β -sympathomimetic drugs in obstetric emergencies. 123, Jul, oa

PROPRANOLOL
Cardiac arrhythmias in pregnant women. 160, 163, Jul, oa

Prescribing FDA-approved drugs in nonapproved ways. 27, Aug, oa

Thyroid storm need not be lethal. 135, 141, 144, Aug, oa

Which therapeutic agents for cardiac arrhythmias? 195, 196, Jul, oa

PROPYLTHIOURACIL
Thyroid storm need not be lethal. 141, Aug, oa

PROSTAGLANDIN E
Managing missed abortion and antepartum fetal death. 17, 20, Sep, pr

PROSTAGLANDIN SYNTHASE
Paracervical block for IUD insertion. Author's reply. 17, Nov, et

PROSTAGLANDINS
PMS—looking for new answers to an old problem. 109, 112, Aug, oa

PROSTHESES
What you should know about reconstructive breast surgery. 178, 191, Nov, oa

PROTEIN BINDING
Obstetric use of local anesthetics. 51, 52, 57, Dec, oa

PROTEINURIA
When your patient has pregnancy-induced hypertension. 36, Oct, pr

PRUNE BELLY SYNDROME
Problems in diagnosing hydronephrosis in utero. 82, Oct, oa

Progress in managing hydronephrosis in utero. 54, 71, Oct, oa

PSYCHIATRY
Long-term effects of rape. 240, Oct, nl

PSYCHOLOGY
How to manage the victim of rape. 253, Sep, oa

New for high-risk ob—the maternal-fetal ICU. 174, Aug, oa

Pediatric gyn trauma. 147, 155, Jul, oa

PSYCHOPHYSIOLOGIC DISORDERS
PMS—looking for new answers to an old problem. 117, 121, Aug, oa

When to refer psychiatric problems. 249, Nov, oa

PSYCHOSEXUAL DISORDERS
Long-term effects of rape. 240, Oct, nl

PUERPERIUM
Contraindications to the gravity suit. 15, Sep, et

PULMONARY EDEMA
For controlling intractable hemorrhage: the gravity suit. 32, Jul, oa

Minimizing side effects from β -adrenergic tocolytics. 171, 172, Oct, oa

PULMONARY WEDGE PRESSURE
Recognizing and treating toxic shock. 50, Jul, oa

PUPP SYNDROME
Your pregnant's rash: Is it PUPP syndrome? 151, Dec, oa

PYELONEPHRITIS
Choosing the best urinary diversion for gyn patients. 260, Nov, oa

PYURIA
Nonobstetric abdominal pain in pregnancy: What's the cause? 71, Jul, oa

QUINIDINE
Cardiac arrhythmias in pregnant women. 163, 164, 166, 174, Jul, oa

Which therapeutic agents for cardiac arrhythmias? 188, 189, Jul, oa

RADIATION
Breast disease—first line of defense. 12, Sep, ed

RADIATION EFFECTS
Is irradiation of gonadal tissue ever safe? 15, Dec, et

Is irradiation of gonadal tissue ever safe? Author's reply. 15, Dec, et

Technique for following irradiated patients. 103, Nov, oa

RADIOGRAPHY
Breast disease—first line of defense. 12, Sep, ed

Lymph node x-rays as possible prognostic indicators. 237, Oct, nl

Managing breech presentation. 18, Jul, et

RADIOIMMUNOASSAY
Chemiluminescence as a biologic marker. 52, 55, 56, T84, oa

Dealing with viral hepatitis during pregnancy. 30, 31, Sep, oa

Immunologic infertility: Which approaches are best? 148, 149, 150, 153, 155, Sep, oa

RADIOThERAPY
Choosing the best urinary diversion for gyn patients. 254, 255, Nov, oa

Is irradiation of gonadal tissue ever safe? 15, Dec, et

Is irradiation of gonadal tissue ever safe? Author's reply. 15, Dec, et

Ovarian Ca—more on cytoreduction. 84, Nov, oa

Radiation lesion may resemble recurrent Ca. 281, Nov, nl

Radiotherapy's benefit for breast cancer dubious. 266, Sep, nl

Small-cell cancer of the cervix. 119, 126, 131, Oct, ppc

Strategy for managing breech presentation. Author's reply. 20, Jul, et

Technique for following irradiated patients. 103, Nov, oa

What treatment alternatives for minimal breast cancer? 113, 116, Oct, oa

RAPE
How to manage the victim of rape. 253, Sep, oa

Long-term effects of rape. 240, Oct, nl

RENAL CIRCULATION
For controlling intractable hemorrhage: the gravity suit. 32, Jul, oa

RESEARCH
Doppler ultrasound detects patent ductus arteriosus early. 221, Aug, nl

How recombinant DNA technology may transform medicine and industry. 203, Aug, oa

Little-known ob-gyn milestone—Mendelson on gastric aspiration. 95, Oct, oa

Preps and enemas—keep or discard? 242, 243, 244, Nov, oa

Safe medications during pregnancy. 55, 56, 60, 63, Nov, oa

Tricks of the trade in displaying data. 87, Sep, oa

Update from San Francisco: the 1983 AFS report. 167, Sep, oa

What matching achieves. 171, Nov, oa

Women at risk for AIDS. 266, Sep, nl

RESEARCH DESIGNS
What matching achieves. 171, Nov, oa

RESPIRATION
Little-known ob-gyn milestone—Mendelson on gastric aspiration. 95, Oct, oa

RESPIRATORY DISTRESS SYNDROME
Prescribing FDA-approved drugs in nonapproved ways. 40, Aug, oa

Recognizing and treating toxic shock. 43, 55, Jul, oa

RESUSCITATION
CPR saving high-risk newborns in San Diego. 220, Aug, nl

RETROPERITONEAL FIBROPLASIA
Using vitamin E to reduce severity of RLF. 268, Sep, nl

RETROPERITONEAL SPACE
Guidelines for exploring the abdomen. 167, Dec, oa

RHEUMATIC FEVER
Genetic marker for rheumatic fever found. 221, Aug, nl

RH-HR BLOOD GROUP SYSTEM
Closing the book on Rh disease. 9, Oct, ed

Managing Rh immunization. 33, Oct, pr

RIFAMPIN
Single source found for six cases of drug-resistant TB. 247, Dec, nl

RNA, MESSENGER
Herpesviruses: why control is difficult. 63, Aug, oa

How recombinant DNA technology may transform medicine and industry. 206, 207, 208, 209, 211, Aug, oa

RUBELLA VACCINE
CDC urges vaccinating adults as rubella in children disappears. 246, Dec, nl

SARCOMA, KAPOSI'S
Herpesviruses: why control is difficult. 68, 72, Aug, oa

SEAWEED
Risk factors for cervical injury in suction D & E. 280, Nov, nl

SECRECTIONS
Diagnostic clues from vaginal odors. 199, 200, Nov, oa

SEmen
Consider the cervical factor in reproduction. 190, Aug, oa

Immunologic immunity: Which approaches are best? 148, Sep, oa

SEMINIFEROUS EPITHELIUM
Intricacies of spermatogenesis. 229, 230, Nov, oa

SEROLOGY
Dealing with viral hepatitis during pregnancy. 30, 31, Sep, oa

SEPTOLI CELLS
Immunologic infertility: Which approaches are best? 146, Sep, oa

233, Nov, oa

SEX BEHAVIOR
Long-term effects of rape. 240, Oct, nl

SEX OFFENSES
Pediatric gyn trauma. 155, Jul, oa

SEXUALLY TRANSMITTED DISEASES
Cervical condyloma and CIN: How are they related? 116, Sep, oa

Colposcopic patterns of papillomavirus infection. 107, Sep, oa

Condyloma concern multiplies over a 15-year period. 221, Aug, nl

Evaluating male partners of condyloma patients. 183, Oct, oa

Herpesviruses: why control is difficult. 61, Aug, oa

How to manage the victim of rape. 255, 257, 258, Sep, oa

HPV and cervical cancer. 239, Oct, nl

Pill's many noncontraceptive benefits. 140, 150, Oct, oa

PPNG infection controlled. 223, Aug, nl

Update from San Francisco: the 1983 AFS report. 184, Sep, oa

SHOCK, HEMORRHAGIC
For controlling intractable hemorrhage: the gravity suit. 25, Jul, oa

SKIN DISEASES
Your pregnant patient's rash: Is it PUPP syndrome? 151, Dec, oa

SMOKING
Cervical cancer risk for teenage smokers. 238, Oct, nl

Fetal activity: measure of well-being. 218, 219, Sep, oa

Pill's many noncontraceptive benefits. 136, Oct, oa

SOCIAL WORK
Helping a patient surrender her child for adoption. 30, 32, Dec, oa

How to manage the victim of rape. 259, Sep, oa

Neonatal death: caring for the parents. 24, Sep, pa

Brief Summary

MINOCIN® Minocycline HCl Oral and Intravenous

CONTRAINDICATIONS: Hypersensitivity to any tetracycline.

WARNINGS: In the presence of renal dysfunction, intravenous use, particularly in pregnancy, in daily doses exceeding 2 grams has been associated with deaths through liver failure. When need for intensive treatment outweighs potential dangers, perform renal and liver function tests before and during therapy; also follow serum concentrations. In renal impairment, usual doses may lead to excessive accumulation and liver toxicity. Under such conditions, use lower total doses, and, in prolonged therapy, determine serum levels. This hazard is of particular importance in parenteral use in pregnant or postpartum patients with pyelonephritis. In such cases, the blood level should not exceed 15 mcg/ml and liver function tests should be made at frequent intervals. Do not prescribe other potentially hepatotoxic drugs concomitantly. **THE USE OF TETRACYCLINES DURING TOOTH DEVELOPMENT (LAST HALF OF PREGNANCY, INFANCY AND CHILDHOOD TO THE AGE OF 8 YEARS) MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH (YELLOW-GRAY-BROWN).** This is more common during long-term use but has been observed following repeated short-term courses. Enamel hypoplasia has also been reported.

TETRACYCLINES, THEREFORE, SHOULD NOT BE USED IN THIS AGE GROUP UNLESS OTHER DRUGS ARE NOT LIKELY TO BE EFFECTIVE OR ARE CONTRAINDICATED. Photosensitivity, manifested by an exaggerated sunburn reaction, has been observed in some individuals taking tetracyclines. Advise patients apt to be exposed to direct sunlight or ultraviolet light that such reaction can occur, and discontinue treatment at first evidence of skin erythema. Studies to date indicate that photosensitivity is rarely reported with MINOCIN minocycline HCl. The antianabolic action of tetracycline may cause an increase in BUN. In patients with significantly impaired renal function, higher serum levels of tetracycline may lead to azotemia, hyperphosphatemia and acidosis. CNS side effects (light-headedness, dizziness, vertigo) have been reported, may disappear during therapy, and always disappear rapidly when drug is discontinued. Caution patients who experience these symptoms about driving vehicles or using hazardous machinery while taking this drug. **Pregnancy:** In animal studies, tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Embryotoxicity has been noted in animals treated early in pregnancy. **Newborns, infants and children:** All tetracyclines form a stable calcium complex in any bone-forming tissue. Prematures, given oral doses of 25 mg/kg every 6 hours, demonstrated a decrease in fibula growth rate, reversible when drug was discontinued. Tetracyclines are present in the milk of lactating women who are taking a drug of this class.

PRECAUTIONS: Use may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, discontinue and institute appropriate therapy. In venereal diseases, when coexistent syphilis is suspected, darkfield examination should be done before treatment is started and blood serology repeated monthly for at least four months. Patients on anticoagulant therapy may require downward adjustment of such anticoagulant dosage. Test for organ system dysfunction (e.g., renal, hepatic and hematopoietic) in long-term use. Treat all Group A beta-hemolytic streptococcal infections for at least 10 days. Avoid giving tetracycline in conjunction with penicillin.

ADVERSE REACTIONS: **G:** (with both oral and parenteral use): anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, inflammatory lesions (with monilial overgrowth) in anogenital region. **Skin:** maculopapular and erythematous rashes. Exfoliative dermatitis (uncommon). Photosensitivity is discussed above ("Warnings"). Pigmentation of the skin and mucous membranes has been reported. **Renal toxicity:** rise in BUN, dose-related (see "Warnings"). **Hypersensitivity reactions:** urticaria, angioneurotic edema, anaphylaxis, anaphylactoid purpura, pericarditis, exacerbation of systemic lupus erythematosus. In young infants, bulging fontanels have been reported following full therapeutic dosage, disappearing rapidly when drug was discontinued. **Blood:** hemolytic anemia, thrombocytopenia, neutropenia, eosinophilia. **CNS:** (see "Warnings"). When given over prolonged periods, tetracyclines may produce brown-black microscopic discoloration of thyroid glands; no abnormalities of thyroid function studies are known to occur.

NOTE: Rapid administration is to be avoided. Parenteral therapy is indicated only when oral therapy is not adequate or tolerated. Oral therapy should be instituted as soon as possible. If intravenous therapy is given over prolonged periods of time, thrombophlebitis may result.

CONCOMITANT THERAPY: Antacids containing aluminum, calcium, or magnesium impair absorption; do not give to patients taking oral minocycline. Studies to date indicate that absorption of MINOCIN is not notably influenced by foods and dairy products.

962-3

LEDERLE LABORATORIES

A Division of American Cyanamid Company
Wayne, New Jersey 07470

EDITORIAL INDEX

New for high-risk ob—the maternal-fetal
ICU. 174, Aug, oa

SONOGRAPHY (see ULTRASOUND)

Progress in managing hydronephrosis in
utero. 47, Oct, oa

SPECIMEN HANDLING

Tracking an elusive entity—microinvasive
cervical cancer. 153, 154, Aug, s

SPECTROPHOTOMETRY

Cervical cytology and CIN: How are they
related? 118, 122, Sep, oa

SPERM

Consider the cervical factor in reproduction.
190, Aug, oa

Effects of marijuana on reproduction. 224,
Oct, oa

Immunologic infertility: Which approaches
are best? 141, Sep, oa

Intricacies of spermatogenesis. 225, Nov,
oa

SPERM AGGLOMERATION

Consider the cervical factor in reproduction.
187, 190, 196, Aug, oa

Immunologic infertility: Which approaches
are best? 148, 149, 150, 153, Sep, oa

SPERM COUNT

Consider the cervical factor in reproduction.
187, Aug, oa

SPERM MOTILITY

Consider the cervical factor in reproduction.

187, 189, 196, Aug, oa

Update from San Francisco: the 1983 AFS
report. 180, Sep, oa

SPERMATOGENESIS

Intricacies of spermatogenesis. 225, Nov,
oa

SPIRONOLACTONE

PMS—looking for new answers to an old
problem. 109, Aug, oa

When to refer psychiatric problems. 250,
Nov, oa

SPLEEN

Guidelines for exploring the abdomen. 167,
170, Dec, oa

STAPHYLOCOCCUS AUREUS

Recognizing and treating toxic shock. 43,
Jul, oa

STERILIZATION

Update from San Francisco: the 1983 AFS
report. 174, Sep, oa

STERILIZATION, TUBAL

Tracking tubal sterilization deaths. 222,
Aug, nl

**STEROIDS (see also SPECIFIC
HORMONE)**

Managing acute adrenal insufficiency. 113,
Jul, oa

PMS—looking for new answers to an old
problem. 109, Aug, oa

STOMACH

Guidelines for exploring the abdomen. 162,
163, Dec, oa

SUDDEN INFANT DEATH

CPR saving high-risk newborns in San
Diego. 220, Aug, nl

How NICU babies fare after discharge. 240,
Oct, nl

SDS cause still elusive. 223, Aug, nl

SURGERY

Choosing the best urinary diversion for gyn
patients. 253, Nov, oa

Consider the cervical factor in reproduction.
196, Aug, oa

Current role of CO₂ lasers in ob-gyn sur-

gery. 107, T84, oa

Expanding the role of β -sympathomimetic
drugs in obstetric emergencies. 140,
Jul, oa

Guidelines for exploring the abdomen. 161,
Dec, oa

How to avoid or minimize urologic injuries in
surgery. 213, Jul, oa

How to choose sutures for microsurgery.
87, Nov, oa

How to induce ovulation. 214, Oct, s

How to select a cryosurgical unit. 101, T84,
nl

How to treat nonobstetric abdominal pain in
pregnancy. 47, Aug, oa

Hysterectomy costs cut by prophylaxis.
237, Oct, nl

Managing acute adrenal insufficiency. 114,
115, Jul, oa

Ovarian Ca—more on cytoreduction. 68,
Nov, oa

Ovarian germ cell tumors. 29, Oct, et

Pediatric gyn trauma. 149, 155, Jul, oa

Problems linked to uterine myomas. 266,
267, 268, 269, 273, 276, Nov, s

Recognizing and treating toxic shock. 55,
Jul, oa

Tracking tubal sterilization deaths. 222,
Aug, nl

Update from San Francisco; the 1983 AFS
report. 169, 170, Sep, oa

What to do when a surgical wound sepa-

rates. 35, Jul, oa

SURGERY, IN UTERO

AMA group weighs benefits of fetal surgery.
247, Dec, nl

SURGICAL TECHNIQUES

Ovarian Ca—more on cytoreduction. 68,
69, 70, 73, 75, Nov, oa

SURGICAL WOUND DEHISCENCE

What to do when a surgical wound sepa-

rates. 35, Jul, oa

SURGICAL WOUND INFECTIONS

Preps and enemas—keep or discard? 243,
244, Nov, oa

SUTURES AND SUTURE TECHNIQUES

How to avoid or minimize urologic injuries in
surgery. 217, 223, Jul, oa

How to choose sutures for microsurgery.
87, Nov, oa

Meeting the challenge of cervical cone bi-

opsy. 87, 88, 96, Dec, oa

Pediatric gyn trauma. 149, Jul, oa

What to do when a surgical wound sepa-

rates. 36, 37, 38, Jul, oa

SYMPATHOMIMETICS

Expanding the role of β -sympathomimetic
drugs in obstetric emergencies. 122,
Jul, oa

TACHYCARDIA

Cardiac arrhythmias in pregnant women.

159, 160, 163, 172, 174, Jul, oa

New diagnostic and therapeutic techniques

TAMOXIFEN
Prescribing FDA-approved drugs in nonapproved ways. 36, 40, Aug, oa

TAMPONS

Recognizing and treating toxic shock. 44, 45, 49, 59, Jul, oa

TECHNOLOGY, MEDICAL

Chemiluminescence as a biologic marker. 47, T84, oa

Chorionic villi sampling: its promise and its problems. Potential for improving fetal treatment. 38, T84, oa

Chorionic villi sampling: its promise and its problems. A source of fetal cells. 31, T84, oa

Ethical decisions: individual or consensus? 11, Jul, ed

How recombinant DNA technology may transform medicine and industry. 203, Aug, oa

NMR—new tool for ob-gyn imaging. 9, T84, oa

Old questions about a new procedure. 3, T84, ed

TERATOGENS

Safe medications during pregnancy. 48, 53, 55, Nov, oa

TERBUTALINE

Prescribing FDA-approved drugs in nonapproved ways. 42, Aug, oa

TESTES

Intricacies of spermatogenesis. 225, Nov, oa

TESTOSTERONE

Effects of marijuana on reproduction. 217, 218, Oct, oa

Immunologic infertility: Which approaches are best? 155, Sep, oa

Intricacies of spermatogenesis. 225, 232, 233, Nov, oa

TETRACYCLINES

How to manage the victim of rape. 257, Sep, oa

Update from San Francisco: the 1983 AFS report. 169, 176, Sep, oa

THC

Effects of marijuana on reproduction. 217, Oct, oa

TERMOGRAPHY

Breast disease—first line of defense. 12, Sep, ed

THYROID

Thyroid storm need not be lethal. 135, 136, 141, 144, 146, Aug, oa

THYROXINE

Thyroid storm need not be lethal. 136, 137, 141, 144, 146, Aug, oa

TOXIC SHOCK SYNDROME

Recognizing and treating toxic shock. 43, Jul, oa

TOXINS

Recognizing and treating toxic shock. 43, Jul, oa

TRANSMISSION, VERTICAL

Dealing with viral hepatitis during pregnancy. 35, 36, 39, Sep, oa

TRANSPORTATION OF PATIENTS

Expanding the role of β -sympathomimetic

drugs in obstetric emergencies. 140, Jul, oa

TRIIODOTHYRONINE

Thyroid storm need not be lethal. 136, 137, 141, 144, 146, Aug, oa

TUBERCULIN TEST

Single source found for six cases of drug-resistant TB. 247, Dec, nl

TUBERCULOSIS

Single source found for six cases of drug-resistant TB. 246, Dec, nl

TWINS

Expanding the role of β -sympathomimetic drugs in obstetric emergencies. 140, Jul, oa

ULTRASOUND

Breast disease—first line of defense. 12, Sep, ed

Chorionic villi sampling: its promise and its problems. Potential for improving fetal treatment. 40, T84, oa

Coping successfully with cord prolapse. 200, 201, 205, Jul, oa

Doppler ultrasound detects patent ductus arteriosus early. 221, Aug, nl

Ensuring optimum outcome for postdate pregnancy. 197, 204, 205, Dec, s

Fetal activity: measure of well-being. 212, 218, Sep, oa

Guide to sinusoidal FHR patterns. 96, 100, Aug, oa

How to induce ovulation. 208, 210, 212, Oct, s

Is it time to retire "IUGR"? 15, Sep, et

Loss of movement dictates evaluation. 15, Oct, et, fm

Managing missed abortion and antepartum fetal death. 17, Sep, pr

Managing placental abruption. 20, 23, Dec, pr

Managing polyhydramnios. 17, 18, 21, Aug, pr

Nonobstetric abdominal pain in pregnancy: What's the cause? 75, 76, Jul, oa

Problems in diagnosing hydronephrosis in utero. 81, 82, Oct, oa

Progress in managing hydronephrosis in utero. 47, Oct, oa

Scanning the pelvis for neoplasia. 115, Dec, oa

Ultrasound and postdate pregnancy. 15, Jul, et

Using the computer to estimate fetal weight. 26, T84, oa

What's available in EFM equipment. 17, 20, T84, oa

When the patient has placenta previa. 17, 18, 20, Dec, pr


When your patient has pregnancy-induced hypertension. 39, Oct, pr

When you suspect ectopic pregnancy. 97, 98, 109, 111, Jul, oa

UMBILICAL CORD

Coping successfully with cord prolapse. 198, Jul, oa

Expanding the role of β -sympathomimetic drugs in obstetric emergencies. 140, Jul, oa



Management of Common Problems in Obstetrics and Gynecology consists of 116 concise, clinically oriented chapters that provide the clinician with the latest diagnostic and therapeutic methods for managing the most commonly encountered obstetric and gynecologic disorders. Features easy-to-find information divided into seven major sections: Obstetrics, Perinatal Medicine, Gynecology, Gynecologic Urology, Gynecologic Oncology, Reproductive Endocrinology and Infertility, and Family Planning. By Daniel R. Mishell, Jr., M.D., and Paul F. Brenner, M.D.

(306-2) 1983 544 pp.
\$32.50 paper

Clip and mail to:



Medical Economics Books
Box 157, Florence, KY 41042

Please send me _____ copies of *Management of Common Problems in Obstetrics and Gynecology* (306-2) @ \$32.50 each. NJ and CA residents add sales tax. Payment must accompany orders when shipping is to a P.O. Box.

30-day return privilege

My payment of \$_____ is enclosed + \$1.50 handling charge. Ship postage paid.
 Bill me, including postage and \$1.50 handling charge.

Name _____ (please type or print)

Title _____

Address _____

City _____

State _____ ZIP _____

COGL3

Tax deductible when used professionally.

EXCEPTIONAL OPPORTUNITY FOR AN OBSTETRICIAN & GYNECOLOGIST (BC) (GENERALIST)

The Department of Obstetrics and Gynecology at St. John's Mercy Medical Center (St. Louis, Missouri), with one of the nation's largest OB service operations, seeks an Obstetrician and Gynecologist with leadership and teaching abilities to join its modern, medically integrated, JCAH accredited facility as Director of its outpatient clinic. The Department has an extremely active clinic, with annual patient visits exceeding 10,500. Call now for additional details or write (with CV) to James G. Blythe, M.D., Chairman, Obstetrics and Gynecology, St. John's Mercy Medical Center, 615 South New Ballas Road, St. Louis, Missouri 63141. (314) 569-6880

EDITORIAL INDEX

URETERAL OBSTRUCTION

Choosing the best urinary diversion for gyn patients. 260, Nov, oa

How to avoid or minimize urologic injuries in surgery. 214, Jul, oa

URETHRAL OBSTRUCTION

Progress in managing hydronephrosis in utero. 52, 54, Oct, oa

URINARY DIVERSION

Choosing the best urinary diversion for gyn patients. 253, Nov, oa

URINARY FISTULA

Choosing the best urinary diversion for gyn patients. 264, Nov, oa

How to avoid or minimize urologic injuries in surgery. 214, 215, 216, Jul, oa

URINARY INCONTINENCE

Choosing the best urinary diversion for gyn patients. 261, Nov, oa

Prescribing FDA-approved drugs in nonapproved ways. 36, Aug, oa

URINARY TRACT INFECTIONS

Classic symptoms may not indicate UTI. 22, Aug, nl

Prescribing FDA-approved drugs in nonapproved ways. 40, Aug, oa

UROGENITAL SYSTEM

Choosing the best urinary diversion for gyn patients. 253, Nov, oa

How to avoid or minimize urologic injuries in surgery. 213, Jul, oa

Progress in managing hydronephrosis in utero. 47, Oct, oa

UROGRAPHY

How to avoid or minimize urologic injuries in surgery. 213, 215, 222, Jul, oa

Progress in managing hydronephrosis in utero. 48, Oct, oa

UTERINE CONTRACTIONS

Coping successfully with cord prolapse. 202, Jul, oa

Fetal distress indicating abruptio placentae. 15, Oct, efm

Protocol for the nipple-stimulation CST. 157, Oct, oa

UTERINE NEOPLASMS

Detecting endometrial cancer and precursor lesions. 231, Sep, s

Problems linked to uterine myomas. 265, Nov, s

Scanning the pelvis for neoplasia. 117, Dec, oa

UTERUS

How to insert an IUD. 163, Sep, cd

Fertility problems of DES daughters. 197, Aug, oa

Managing missed abortion and antepartum fetal death. 17, Sep, pr

New instruments and techniques for hysteroscopy. 67, 68, 71, T84, oa

Problems linked to uterine myomas. 265, Nov, s

VACCINATION

CDC urges vaccinating adults as rubella in children disappears. 246, Dec, nl

VACUUM CURETTAGE

Risk factors for cervical injury in suction D & E. 280, Nov, nl

VAGINA

Diagnostic clues from vaginal odors. 199, Nov, oa

Flexible prescribing of estrogens. 142, 145, 146, Nov, oa

Technique for following irradiated patients. 103, 104, 106, Nov, oa

VAGINAL CREAMS, FOAMS AND JELLIES

Flexible prescribing of estrogens. 159, 162, Nov, oa

VAGINITIS

Colposcopic patterns of papillomavirus infection. 110, 112, Sep, oa

Diagnostic clues from vaginal odors. 199, 218, 219, 220, Nov, oa

Prescribing FDA-approved drugs in nonapproved ways. 36, Aug, oa

VARIABLES

Tricks of the trade of displaying data. 87, Sep, oa

VARICELLA-ZOSTER VIRUS

Herpesviruses: why control is difficult. 61, 62, 63, 72, 74, Aug, oa

VASECTOMY

Immunologic infertility: Which approaches are best? 146, 148, Sep, oa

VASOCONSTRICTOR

Obstetric use of local anesthetics. 54, 56, Dec, oa

VASODILATION

Obstetric use of local anesthetics. 51, 57, Dec, oa

VENEREAL DISEASES (see SEXUALLY TRANSMITTED DISEASES)

VENTRICULAR FIBRILLATION

Cardiac arrhythmias in pregnant women. 174, Jul, oa

VERAPAMIL

Cardiac arrhythmias in pregnant women. 163, Jul, oa

VESICOVAGINAL FISTULAS

How to avoid or minimize urologic injuries in surgery. 219, 222, 223, Jul, oa

VITAMIN DEFICIENCY

PMS—looking for new answers to an old problem. 106, Aug, oa

VITAMINS

Lumps: When is close follow-up appropriate? 200, Sep, oa

PMS—looking for new answers to an old problem. 106, Aug, oa

Using vitamin E to reduce severity of RLF. 268, Sep, nl

When to refer psychiatric problems. 250, Nov, oa

WOLFF-PARKINSON-WHITE SYNDROME

Cardiac arrhythmias in pregnant women. 180, 184, Jul, oa

WORK

Work and pregnancy: guidelines needed. 9, Aug, ed

WOUNDS AND INJURIES

For controlling intractable hemorrhage: the gravity suit. 22, Jul, oa

Pediatric gyn trauma. 148, 149, 155, Jul, oa

What can we do for Mrs. Smith? 11, Nov, ed

